

# Current and Past Strategies for Bacterial Culture in Clinical Microbiology

Jean-Christophe Lagier, Sophie Edouard, Isabelle Pagnier, Oleg Mediannikov, Michel Drancourt, Didier Raoult

Aix Marseille Université, URMITE, UM63, CNRS 7278, IRD 198, INSERM 1095, Marseille, France

SUMMARY .....	209
INTRODUCTION .....	209
EARLY STRATEGIES AND GENERAL PRINCIPLES .....	209
Nonselective Culture Media .....	210
Solid agar and coagulated serum .....	210
Enriched media .....	210
Selective Culture Media .....	210
Organic and inorganic components and minerals .....	210
Antibiotics and antiseptics .....	210
Sample Decontamination .....	210
Temperature and Atmosphere Control .....	210
Temperature .....	210
Atmospheres .....	210
(i) Aerophilic and anaerobic conditions .....	210
(ii) Microaerophilic conditions .....	210
Incubation Time .....	210
Improving Collection and Transport Time to the Laboratory .....	211
SPECIFIC STRATEGIES FOR FASTIDIOUS BACTERIA .....	211
<i>Mycoplasma</i> .....	211
Anaerobes .....	211
Brief history of earlier methods .....	211
(i) Physical reduction of oxygen tension .....	211
(ii) Chemical reduction by reducing agents .....	211
Constituents of anaerobic media .....	212
(i) Major and minor constituents of suitable anaerobic media .....	212
(ii) Growth factors .....	212
Anaerobic incubation systems used to increase the ability to cultivate anaerobes .....	212
(i) Anaerobic jars .....	212
(ii) Roll tube method .....	212
(iii) Anaerobic chambers .....	212
Perspectives on anaerobic culture .....	212
Spirochetes .....	212
Mycobacteria .....	214
<i>Archaea</i> .....	215
INTRACELLULAR BACTERIAL CULTURE .....	217
Culture in Embryonated Eggs .....	217
Animal Inoculation .....	217
Coculture with Amoebae .....	218
History .....	218
Methods .....	218
(i) Coculture with amoebae .....	218
(ii) Isolation of wild amoebae with their symbionts .....	219
(iii) Protozoa used for ARM culture .....	219

(continued)

**Citation** Lagier J-C, Edouard S, Pagnier I, Mediannikov O, Drancourt M, Raoult D. 2015. Current and past strategies for bacterial culture in clinical microbiology. Clin Microbiol Rev 28:208–236. doi:10.1128/CMR.00110-14.

Address correspondence to Didier Raoult, didier.raoult@gmail.com.

Copyright © 2015, American Society for Microbiology. All Rights Reserved.

doi:10.1128/CMR.00110-14

Results .....	219
(i) Alphaproteobacteria .....	219
(ii) Betaproteobacteria .....	219
(iii) Gammaproteobacteria .....	219
(iv) Epsilonproteobacteria .....	220
(v) Firmicutes .....	220
(vi) Bacteroidetes .....	220
(vii) Actinobacteria .....	220
(viii) Chlamydia .....	220
(ix) Endomicrobia .....	220
(x) TM6 phylum .....	221
Use in clinical microbiology .....	221
Perspectives .....	221
Cell Culture .....	221
Cell lines grown at 37°C .....	221
Cell lines grown at 28°C .....	222
Specific devices (shell vial) .....	222
Axenic Culture Media for Intracellular Bacteria .....	223
<i>Coxiella burnetii</i> .....	223
<i>Tropheryma whippelii</i> .....	224
<i>Chlamydia</i> species .....	224
Empirical broad-spectrum medium .....	224
Future challenges .....	225
CONCLUSION .....	225
ACKNOWLEDGMENTS .....	225
REFERENCES .....	225
AUTHOR BIOS .....	235

## SUMMARY

A pure bacterial culture remains essential for the study of its virulence, its antibiotic susceptibility, and its genome sequence in order to facilitate the understanding and treatment of caused diseases. The first culture conditions empirically varied incubation time, nutrients, atmosphere, and temperature; culture was then gradually abandoned in favor of molecular methods. The rebirth of culture in clinical microbiology was prompted by microbiologists specializing in intracellular bacteria. The shell vial procedure allowed the culture of new species of *Rickettsia*. The design of axenic media for growing fastidious bacteria such as *Tropheryma whippelii* and *Coxiella burnetii* and the ability of amoebal coculture to discover new bacteria constituted major advances. Strong efforts associating optimized culture media, detection methods, and a microaerophilic atmosphere allowed a dramatic decrease of the time of *Mycobacterium tuberculosis* culture. The use of a new versatile medium allowed an extension of the repertoire of archaea. Finally, to optimize the culture of anaerobes in routine bacteriology laboratories, the addition of antioxidants in culture media under an aerobic atmosphere allowed the growth of strictly anaerobic species. Nevertheless, among usual bacterial pathogens, the development of axenic media for the culture of *Treponema pallidum* or *Mycobacterium leprae* remains an important challenge that the patience and innovations of cultivators will enable them to overcome.

## INTRODUCTION

As proposed by Robert Koch, a pure culture is the foundation of all research in infectious diseases (1, 2). The first isolation of a bacterium enables the design of experimental models to analyze virulence and to complete Koch's criteria, thereby establishing a link between microorganisms and infectious diseases (3). Bacterial culture also enables the study of the antibiotic suscepti-

bility of bacteria and is the first step in establishing recommendations for effective treatment (4, 5). Obtaining a pure bacterial culture also enables genome sequencing of these strains (6, 7) and proteomic studies to highlight specific proteins and analyze their antigenicity by immunoproteomic techniques, eventually facilitating the production of these proteins, which serve as antigens for serologic tests (8). Finally, pure bacterial culture enables manipulation and transformation by adding or deleting genes to analyze the cause of virulence and antibiotic resistance and the invasive potential of bacteria. However, over the last 30 years, the same progress observed with molecular biology has not emerged with culture in clinical microbiology (9).

Bacterial culture is frequently more difficult and often requires more training than molecular techniques. Consequently, the number of microbiologists specializing in anaerobic bacteria has declined steadily for 30 years, and currently, there are few specialists compared with the number of specialists during the 1970s. Renewed interest in bacterial culture was initiated in large part by clinical microbiologists (10–12) specializing in intracellular bacteria. They have developed axenic media, which are sterile media containing no living organism except the one being cultivated, to culture extremely fastidious bacteria (11, 13, 14). We propose here, after a brief report of early strategies of culture, a comprehensive review regarding past and current culture techniques used for the culture of fastidious bacteria. In an additional review, we elaborate on the progresses allowed by new identification methods and the application of all these advances through the example of the study of human gut microbiota by culturomics (15).

## EARLY STRATEGIES AND GENERAL PRINCIPLES

The first culture media were developed empirically, using environmental components. Overall, the choice of nutrients, atmosphere, temperature, and time of incubation are the 4 primary elements that determine the growth of bacteria (16).

## Nonselective Culture Media

Nonselective culture media contain no inhibitors and should permit the growth of most of the microorganisms present in the clinical samples studied. Meat infusions or heart or brain extracts were the initial substrates used empirically. Yeast extracts remain among the major components of several culture media (17). Vegetable components can also be used (18).

Peptones, which are carbohydrate-free sources of nutrients, defined as soluble products from the enzymatic hydrolysis of proteins, are more often used as nutrient additives in culture media. Diverse enzymes can be distinguished, and the diverse substrates are meat, casein, soya, and gelatin.

**Solid agar and coagulated serum.** Clinical microbiology was revolutionized by the invention of the petri dish (19), which, because of the use of a transparent lid, has allowed us to observe colonies and to limit contamination. The addition of kitchen components, such as gelatin or agar, has led to the design of solid culture media (20) and, consequently, the possible description of bacterial species in pure culture. The use of solid culture media and petri dishes was probably comparable to the progress by Koch and Pasteur in modern clinical microbiology. Other solidifying components can be used, such as coagulated eggs, as in Lowenstein-Jensen medium, which is used for *Mycobacterium* culture (21). Coagulated serum can also be used, notably in Loeffler medium, which was designed for performing *Corynebacterium* culture (22).

**Enriched media.** Enriched media are designed to facilitate the growth of fastidious microorganisms. The primary enrichment component is blood, which provides hemin and other nutrients. This component is frequently added to agar media in several commercial media to notably increase the growth of anaerobic bacterial species (23). Blood agar, which was initially accidentally used for *Mycobacterium tuberculosis* culture, was also shown to be a cost- and time-effective method, with better growth than with the egg-based agar reference medium (24, 25).

## Selective Culture Media

In clinical microbiology, a challenge has been to isolate the pathogenic microorganisms from complex microbiota in pure culture (26).

**Organic and inorganic components and minerals.** Deoxycholic acids are frequently used as Gram-positive bacterial inhibitors. Bile salts are also used as Gram-positive inhibitors, while crystal violet inhibits the growth of Gram-positive bacteria (26). Bismuth sulfite agar uses the ability of bismuth to inhibit most Gram-positive and Gram-negative commensal organisms for the culture of enteric bacilli (26). Finally, Chapman agar is based on the ability of staphylococci to grow in culture media with a high NaCl concentration (7.5%) (26).

**Antibiotics and antiseptics.** Antibiotics are not specific to bacterial species and generally inhibit the growth of many bacterial genera or species. As examples, ANC (nalidixic acid and colimycin) medium promotes the specific growth of Gram-positive bacteria, and *Campylobacter* blood agar is an enriched selective medium that contains 5 different antimicrobial agents. Antibiotics are used in *Mycobacterium* culture media primarily as a cocktail that includes polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin (27). Antiseptics, such as bromocresol purple, were used previously in agar culture media to select *Enter-*

*obacteriaceae* in particular, with different uses, such as the isolation of injured coliforms from drinking water (28).

## Sample Decontamination

Another strategy is to decontaminate the samples to decrease the rapid overgrowth common in commensal bacteria (21). The *N*-acetyl-L-cysteine-NaOH method was initially used for culturing *Mycobacterium* spp. (29). Chlorhexidine (30) was used to decontaminate the sputum of cystic fibrosis patients, with the aim of culturing nontuberculous mycobacteria (31). El Khechine et al. used chlorhexidine to decontaminate stool samples before *Mycobacterium* species culture (32). This noninvasive method obviates the requirement for gastric aspiration without a difference in pulmonary tuberculosis diagnosis (33). Finally, lytic phages have been used to decontaminate the normal flora from sputum before *M. tuberculosis* culture to replace the use of antibiotics (27, 34).

## Temperature and Atmosphere Control

**Temperature.** Most of the species implicated in clinical microbiology are mesophilic bacterial species, and these species grow at medium temperatures of 25°C to 45°C. In clinical microbiology, one of the most famous examples of the requirement for the use of an adapted temperature for growth was highlighted by *Rickettsia felis* (35). After failing to grow the bacterium in human embryonic lung (HEL) cells at 37°C, researchers suspected that temperature growth was critical because this factor had been reported for many arthropod-borne microorganisms (36–39). Finally, the first cell culture of *R. felis* was performed, using XTC2 cells obtained from *Xenopus laevis* oocytes growing at 28°C, which were usually used for arboviruses (39, 40).

**Atmospheres. (i) Aerophilic and anaerobic conditions.** Various atmospheres can be used in clinical microbiology. To describe microbes from human feces, roll tubes (defined precisely in the section on anaerobic methods, below) were previously designed (41). Nottingham and Hungate first used a nonselective medium but a stringent atmosphere consisting of 80% H<sub>2</sub> and 20% CO<sub>2</sub> to isolate nonidentified methanogenic *Archaea* from humans (42).

**(ii) Microaerophilic conditions.** When the concentration of oxygen required to obtain growth is relatively low, the bacterial species are considered microaerophiles, such as *Campylobacter* spp., which can cause human infections involving primarily the gastrointestinal tract (43). Most *Campylobacter* species require a microaerobic atmosphere containing ~5% O<sub>2</sub>, 10% CO<sub>2</sub>, and 85% N<sub>2</sub> for optimal recovery. Recently, a microaerophilic atmosphere demonstrated better efficiency than aerobic conditions in promoting *Mycobacterium* culture and was proposed as a routine condition for laboratories performing these cultures (44).

## Incubation Time

Most clinical pathogens grow easily over 24 to 48 h in plate media (45), but several bacterial species require a much longer time, whereas most routine laboratories maintain cultures within 5 days. As a common example, *Helicobacter pylori*, the bacterium causing most gastrointestinal ulcers, requires a longer incubation period. Petri dishes with bacterial cultures were inadvertently left by B. Marshall in the incubator for 5 days (46). Thereafter, he observed small colonies constituting the first successful culture and isolation of a bacterium from the stomach of a patient suffering from gastritis. The association between the bacterium and gastritis was met with great skepticism by the scientific commu-

nity, and to confirm this association, Marshall inoculated himself by drinking a solution containing vast amounts ( $10^9$ ) of the bacterium. He developed acute gastritis, confirming Koch's postulates that the bacterium was the causative agent (3).

As another example, human infections caused by *Bartonella* species can cause trench fever; cat scratch disease; and, under particular conditions, bacillary angiomatosis, peliosis hepatitis, endocarditis, or chronic lymphadenopathies (47–49). Usually, the growth of *Bartonella* spp. is slow, requiring 12 to 14 days when blood agar is used, with certain isolates sometimes requiring longer incubation periods of >45 days (48). *Bordetella pertussis* colonies are visible in 3 to 4 days, (18), and *Legionella pneumophila* colonies usually appear on day 3 (50). Fecal samples should be incubated for at least 3 days to culture *Campylobacter* spp. (43). For the isolation of aerobic actinomycetes, such as *Nocardia* spp. and *Actinomyces* spp., an incubation time ranging from 2 to 3 weeks is recommended (51). Finally, for routine clinical microbiology, anaerobic species cultures should be incubated for at least 5 days (45).

### Improving Collection and Transport Time to the Laboratory

The viability of organisms depends on several factors, such as transport time, storage period, temperature (52), as well as specific storage systems to ensure that the microorganism's viability is maintained, although clinical or research samples should ideally be cultivated immediately after sampling. The use of an inefficient sampling device will lead to a misidentification of pathogens due to contaminant growth resulting from oxygen exposure or from an extremely small fraction of bacteria being recovered. Because of their low cost, utility, ease of use, and availability, swabs are still used to collect and transport various sample types (53, 54). New swab types have been designed (55) to improve specimen collection, such as the new nylon-flocked swab with Amies liquid medium, which is more effective in bacterial recovery and which provides for more efficient release than classic swabs (54).

## SPECIFIC STRATEGIES FOR FASTIDIOUS BACTERIA

### *Mycoplasma*

*Mycoplasma* spp. do not have cell walls (56) and do not stain by Gram coloration. In 1898, Nocard and Roux reported the first culture of *Mycoplasma mycoides* subsp. *mycoides*, which is the agent of bovine pleuropneumonia (57), 15 to 20 days after inoculation of a semipermeable collodion sac. In 1960, *Mycoplasma mycoides* was successfully cultured in a medium that included a heat-stable defatted serum protein fraction, cholesterol, both saturated and unsaturated fatty acids, serum albumin, glycerol, and high concentrations of DL- or L-lactate and glucose (58, 59). For diverse strains of *Mycoplasma* (known at that time as pleuropneumonia-like organisms [PPOs]) (60), a variety of substances were used as supplements, including blood serum or ascitic fluid (61), lipid extracts of egg yolk, cholesterol (62), lipoprotein, lecithin, and acetate (63, 64). The Eaton agent (*Mycoplasma pneumoniae*) was first cultured in a cell-free medium consisting of 70% Difco PPLO agar, 10% of 25% boiled yeast extract, and 20% unheated horse serum (65). *M. pneumoniae* was successfully isolated directly from patients with atypical pneumonia by using this medium and adding penicillin, amphotericin, and thallos acetate (66). Chanock et al. proposed an effective medium (65), and Tully et al. then developed the refined SP4 medium in 1979, which be-

came the most widely used broth and agar medium for culturing of *M. pneumoniae* from clinical samples (67). This medium contains tryptone, peptone, PPLO broth, heat-inactivated fetal bovine serum, yeast extract, Yeastolate, and CMRL 1066 medium (67). *Ureaplasma urealyticum* (also called T-strain mycoplasma for tiny colonies) causes genital infections in humans. The total growth of *Ureaplasma urealyticum* was directly correlated with urea concentrations, with a maximum yield of organisms being observed with a 32 mM urea concentration. Finally, the addition of SP4 medium, glucose, urea, or arginine, depending on the suspected *Mycoplasma* species, was proposed. Indeed, common human mycoplasmas were then distinguished by 4 biochemical tests: glucose oxidation, arginine deamination, urea hydrolysis, and methylene blue reduction or growth inhibition.

### Anaerobes

Anaerobes are generally widespread, can be found in the environment, and are members of the normal human flora (68–70), but only a few species are frequently encountered in significant human infections (71). The sensitivity of anaerobes to oxygen differs depending on the species (72, 73). Loesche et al. (72) classified bacteria into three different categories according to their oxygen sensitivity: strict (bacteria cannot grow on medium with a partial  $O_2$  pressure [ $pO_2$ ] of >0.5%) (73, 74), moderate (bacteria can grow in the presence of oxygen levels of between 2 and 8%) (72), and microaerotolerant (growth occurs in the presence or absence of oxygen in the medium; however, maximal growth occurs at intermediate oxygen levels) (72).

Culturing of strictly anaerobic bacteria in the absence of oxygen requires specific bacteriological techniques, which could explain the low frequency of isolation in many laboratories (75, 76). Therefore, strictly anaerobic bacteria require complex media with many supplements for growth (77–81). Hungate revolutionized the culture of anaerobic species by cultivating extremely oxygen-sensitive microorganisms, such as sulfate-reducing bacteria and methanogenic *Archaea* (76).

**Brief history of earlier methods.** The equipment required for maintaining reduced oxygen tension (77, 78) is simple and inexpensive. First, most of the oxygen is removed and is replaced by a suitable gas source.

(i) **Physical reduction of oxygen tension.** The more commonly used technique for obtaining free  $O_2$  medium consisted of using carbon dioxide or hydrogen through or over the surface of the medium to replace oxygen (82). Additionally, the candle technique was commonly used to cultivate anaerobes (83–85). This technique consisted of burning a candle inside a sealed jar to replace the oxygen with  $CO_2$ , which resulted in the production of 3%  $CO_2$  under standard conditions (84).

(ii) **Chemical reduction by reducing agents.** Strictly anaerobic bacteria grow in an almost total absence of oxygen, which is often toxic (70). These bacteria must be grown in a reducing atmosphere, in which energy is produced by fermentation or anaerobic respiration (86). Chemical techniques were based on reducing oxygen tension by adding reducing agents such as thioglycolate, glutathione, cysteine-HCl, sodium sulfide ( $Na_2S$ ) (82), or sodium carbonate-oxalic acid (84). Ascorbic acid-supplemented medium can also be used as an anaerobic medium. Recently, La Scola et al. successfully performed an aerobic culture of 6 strictly anaerobic species, including *Fusobacterium necrophorum*, using Schaedler agar supplemented with high-dose ascorbic acid or glutathione

and with pH adjustment to 7.2 (87), suggesting substantial perspectives in routine bacteriology.

**Constituents of anaerobic media.** Freshly prepared, highly enriched, and properly stored medium has been essential to enhance anaerobic bacterial growth (88, 89).

**(i) Major and minor constituents of suitable anaerobic media.** Anaerobic media must contain carbon sources, electron acceptors, and donor elements (90). The major constituents of suitable growth medium are represented by macroelements and metals in sufficient quantities (90), because the typical composition depends on a percentage of microbial dry mass (91). The addition of minor constituents (trace elements) is not required because most microorganisms use a unique carbon source to grow. Moreover, it is difficult to demonstrate which growth factor is required for an organism to allow better growth and which factor is essential (90). Nevertheless, a few bacteria require specific focus and particular constituents, such as many *Bacteroides* strains, which require the addition of vitamin K<sub>1</sub> and hemin to the medium for growth (92).

**(ii) Growth factors.** Growth factors of undefined composition, such as yeast extract and pyrimidines (93), peptone (93), Casitone, Casamino Acids, or clarified rumen fluid, are still preferably added to culture media (90). These fluids contain volatile fatty acids and heme, which are not commonly found in the extracts or hydrolysates added to classical media (94). These fluids have been supplemented with glycerol, Trypticase, hemin, and mineral solutions 1 and 2 (modified 98-5 medium) (95) and sometimes with sterilized fecal extract (92) to allow higher percentages of anaerobe recovery than with other analyzed media (95, 96). Further studies were performed in humans, and human sterilized fecal samples have been used as a nutrient source to provide specific anaerobe growth (42, 97).

**Anaerobic incubation systems used to increase the ability to cultivate anaerobes.** Clinical laboratories may prefer to use anaerobic jars and anaerobic chambers rather than roll tubes because of the delay and because of the complexity of this method. The Hungate technique may be used particularly for research activity (98).

**(i) Anaerobic jars.** Currently, the GasPak system produces an atmosphere containing ~10% CO<sub>2</sub> with sachets containing a dry powder or pellets of sodium borohydride and sodium bicarbonate, which react with water to produce hydrogen gas and carbon dioxide. The hydrogen produced then reacts with oxygen gas on a palladium catalyst, allowing greater water production to remove the oxygen gas (74). Anaerobic jars do not allow a continuously anaerobic atmosphere from sample reception to seeding to be established, and their use is inadequate for cultivating certain strictly oxygen-sensitive bacteria (72).

**(ii) Roll tube method.** The Hungate method, which is based on the use of roll tubes, was introduced to prepare an anoxygenic medium for methanogen cultivation (99, 100). The principle is based on replacing atmospheric oxygen with other gases, such as N<sub>2</sub>, CO<sub>2</sub>, H<sub>2</sub>, or other mixtures with adjusted pH (101), using an anaerobic glove box. After incorporation of all the elements, the medium is mixed and then boiled in an oxygen-free nitrogen atmosphere in the presence of resazurin as an indicator of the presence of oxygen. After resazurin reduction, the medium is cooled under nitrogen at room temperature. The flask is then capped and transferred to the anaerobic glove box, where the medium is distributed into serum vials or Hungate tubes. The containers are sealed with plastic stoppers, and the media are then sterilized in an autoclave before inoculation (76). The isolated colonies then form

on the walls of the tubes after several days or weeks of incubation (101). The roll tube method greatly improves anaerobic growth (102) and remains the reference method for methanogens and archaea; however, this technique remains time-consuming and rather complex for large-scale studies due to the requirement for the use of roll tubes instead of petri dishes and cannot be used in clinical laboratories (99).

**(iii) Anaerobic chambers.** The best method to ensure anaerobe viability is to incubate anaerobic organisms directly in an anaerobic chamber (103, 104), never allowing exposure of the sample to air (105). This method, which is usable in both research and clinical laboratories because it does not require special training (106), is inexpensive. A prerduced medium with low redox potential is used to seed the samples.

**Perspectives on anaerobic culture.** The human gut microbiota is the human site that contains a higher concentration of anaerobes (9). In future research projects, it may be important to continue to characterize human anaerobic microflora by high-throughput sequencing, to identify anaerobic clusters, and to design new anaerobic strategies that use antioxidant agents (87) that allow the cultivation of uncultivated anaerobic bacteria. This approach will clearly revolutionize the culture of anaerobic bacteria in routine bacteriology and in culturomics studies.

## Spirochetes

Although most spirochetes are free-living chemoorganotrophs, spirochetes of the genera *Borrelia*, *Treponema* (*Spirochaetaceae*), and *Leptospira* (*Leptospiraceae*) are major human pathogens (107). Many members of the genus *Brachyspira* are important veterinary pathogens but occasionally have been reported to be associated with human pathology (108–110). *Spirochaetes* are often not visible by Gram staining, requiring dark-field microscopy or special coloration (111). Molecular identification is usually based on group-specific *flaB*, *ospA*, *ospB*, and *ospC* genes and *rrf* (5S)-*rrl* (23S) intergenic spacer amplification (112). Among conservative housekeeping genes, *rpoB* could be a useful tool (113).

All borreliae are fastidious organisms and chemoheterotrophic and use carbohydrates, amino acids, long-chain fatty acids, or long-chain fatty alcohols as carbon and energy sources. Depending on the species, growth occurs under anaerobic, facultatively anaerobic, microaerophilic, or aerobic conditions (114). Because of the lack of or limited biosynthetic potential (the ability to elongate long-chain fatty acids to synthesize most amino acids, enzyme cofactors, and nucleotides), complex nutritional requirements are needed for spirochete cultivation.

*Leptospira interrogans* was previously considered the only species of this genus that is pathogenic in humans; however, a phylogenetic analysis of all isolated strains showed that among 22 currently recognized species (<http://www.bacterio.net/leptospira.html>), leptospirosis-causing bacteria belong to at least 11 different species (115, 116) (see Table 2). Leptospirae can be isolated by inoculating ~100 µl of a patient's blood in solid or semisolid oleic acid, which is an albumin-containing medium. Several media are available, namely, EMJH (117), polysorbate medium (118), and LVW agar (119). The presence of rabbit serum, polysorbates, and vitamins is essential.

Four different *Treponema* spp. are human pathogens, including 3 subspecies of *T. pallidum* (*T. pallidum* subsp. *pallidum* [syphilis], subsp. *pertenue* [yaws], and subsp. *endemicum* [nonvenereal epidemic syphilis]) and the pinta agent *T. carateum*. None of these pathogens has yet been successfully cultivated in axenic medium,




FIG 1 Thick smear of mouse blood showing *Borrelia hispanica* strain OM003 (Giemsa staining). Magnification,  $\times 900$ .

and isolation in pure culture is not a diagnostic option. *Treponema pallidum* subsp. *pallidum* can be propagated only in laboratory animals (rabbits) by intratesticular, intradermal, intravenous, or intracisternal inoculation (120). *T. pallidum* grows slowly, with a doubling time of 30 to 33 h (107), and a mean of  $10^{10}$  bacteria has been harvested from the testis of a rabbit. *Treponema paraluis-cuniculi*, which is the causative agent of rabbit venereal spirochetosis, is genetically closely related to *T. pallidum* (121) and easily infects laboratory rabbits. The closely related agents of yaws and nonvenereal epidemic syphilis share similar features; however, their culture has been even less studied. *T. carateum* has also never been isolated; moreover, there are no successful animal model. These organisms are among the last few as-yet-uncultured major human pathogens. Similarly, among the numerous *Treponema* phylotypes found in the oral cavity, only 10 different species have been cultivated, with *Treponema denticola* being the most extensively studied (122). The development of an axenic culture of pathogenic *Treponema* remains a challenge for microbiologists.

The genus *Borrelia* is essentially composed of the Lyme disease group and the relapsing fever group (123–125). Many *Borrelia* species, particularly those species of the Lyme disease group, are routinely cultured in liquid Barbour-Stoenner-Kelly II (BSK-II) medium under microaerophilic conditions (126, 127) or its variations, such as BSK-H (128), at 30°C to 34°C. Despite the existence of other media such as MPM (129), inoculation of clinical samples (blood or skin lesion biopsy specimens) or triturated ticks in BSK medium remains the most reliable approach for isolating Lyme disease borreliae. Successful culture of these fastidious organisms has also been achieved in BSK medium solidified with 1.5% agarose (130). Contaminants can be eliminated by adding nalidixic

acid and 5-fluorouracil (126, 131). These organisms grow slowly, dividing every 8 to 12 h during the exponential growth phase. Primary strains from clinical samples and ticks can take as long as several weeks to grow; however, culture-adapted isolates can reach cell densities of  $10^7$  to  $10^8$  cells per ml after cultivation *in vitro* for 5 to 7 days.

Isolation by animal inoculation was the first and most reliable method for the isolation of relapsing fever borreliae. BSK medium incubated at 35°C was also used to isolate *Borrelia recurrentis* from the serum of a patient with louse-borne relapsing fever (132). One bacterium is sufficient to produce infection in laboratory animals, including mice, rats, rabbits, guinea pigs, and monkeys (133), but the mouse is the most susceptible animal, producing high-level borreliemia (reaching the maximum at 3 to 6 days) (134). However, within 10 to 14 days postinoculation, when bacteria disappear from the blood, the bacteria can still be found in the reticuloendothelial system or in other organs of infected animals, primarily in brain, where borreliae persist for a longer time (133, 135). The genome of *Borrelia miyamotoi* was obtained from *Borrelia* cells present in the blood of infected mice (136).

Similar to its use on Lyme disease borreliae, BSK-II medium was also used for isolating and culturing *Borrelia duttonii* from patients' blood specimens (137) and for culturing *Borrelia crocidurae* from ticks in Mali (138). Successful isolation was achieved by inoculating blood specimens at room temperature, with subsequent blind subculture every 3 days in fresh medium at 33°C. Bovine serum albumin fraction V complement seems to be an extremely important component of this medium. *Borrelia hispanica* is particularly difficult to isolate in axenic medium (124), and animal inoculation remains the method of choice (Fig. 1). For

TABLE 1 Culture strategies for isolating spirochetes related to human pathology

Family	Genus and species	Pathogenicity for humans	Culture method(s) <sup>a</sup>
<i>Brachyspiraceae</i>	<i>Brachyspira aalborgi</i>	Colonizes human gut, most likely associated with diarrhea	Tryptose soy blood agar plates + 10% calf blood, 38.5°C in an anaerobic atmosphere (95% H <sub>2</sub> -5% CO <sub>2</sub> )
	<i>Brachyspira pilosicoli</i>	Colonizes human gut, most likely associated with diarrhea	Tryptose soy blood agar plates + 10% calf blood, 38.5°C in an anaerobic atmosphere (95% H <sub>2</sub> -5% CO <sub>2</sub> ) + BHIS broth or HS broth containing carbohydrates
	<i>Brachyspira hominis</i>	Colonizes human gut, most likely associated with diarrhea	Not yet isolated
<i>Leptospiraceae</i>	<i>Leptospira interrogans</i> , <i>L. kirschneri</i> , <i>L. noguchii</i> , <i>L. borgpetersenii</i> , <i>L. weilii</i> , <i>L. santarosai</i> , <i>L. alexanderi</i> , <i>L. alstonii</i> , <i>L. kmetyi</i> , <i>L. broomii</i> , <i>L. fainei</i>	Human pathogens, leptospirosis	Nonsolid or semisolid (0.1–0.2% agar) oleic acid and albumin-containing media at 30°C; some fastidious strains can require 6 mo of incubation
<i>Spirochaetaceae</i>	<i>Treponema pallidum</i> subsp. <i>pallidum</i>	Syphilis	Intratesticular inoculation of clinical samples or bacterial strains in a rabbit model
	<i>Treponema pallidum</i> subsp. <i>pertenue</i>	Yaws	Intratesticular inoculation of clinical samples or bacterial strains in a rabbit model
	<i>Treponema pallidum</i> subsp. <i>endemicum</i>	Nonvenereal epidemic syphilis	Intratesticular inoculation of clinical samples or bacterial strains in a rabbit model
	<i>Borrelia carateum</i>	Pinta	Not yet isolated
	<i>Borrelia burgdorferi</i> , <i>B. afzelii</i> , <i>B. garinii</i> , <i>B. valaisiana</i> , <i>B. lusitanae</i> , <i>B. bissettii</i> , <i>B. spielmanii</i>	Lyme disease	BSK-II, BSK-H, MKP, MPM media; microaerophilic conditions at 30°C–34°C
	<i>Borrelia miyamotoi</i>	Unnamed fever	BSK-II medium at 31°C, severe combined immunodeficient mice <sup>b</sup>
	<i>Borrelia recurrentis</i>	Louse-borne relapsing fever	BSK medium, susceptible animals (mice, rats, rabbits, guinea pigs, and monkeys)
	<i>Borrelia duttonii</i>	Tick-borne relapsing fever, East Africa	BSK medium, susceptible animals (mice, rats)
	<i>Borrelia crocidurae</i>	Tick-borne relapsing fever, West Africa	BSK medium, susceptible animals (mice, rats)
	<i>Borrelia hispanica</i>	Tick-borne relapsing fever, North Africa, Europe	Only mouse model
	<i>Borrelia hermsii</i>	Tick-borne relapsing fever, North America	BSK medium, mouse model
	<i>Borrelia turicatae</i> , <i>B. parkeri</i>	Possible tick-borne relapsing fever, North and South America	BSK medium
	<i>Borrelia persica</i>	Tick-borne relapsing fever, Central Asia	Guinea pig and mouse models; after sensitization, BSK medium
	<i>Borrelia microti</i>	Possible tick-borne relapsing fever, Asia	Mouse model
<i>Borrelia baltazardii</i> , <i>B. caucasica</i> , <i>B. latyschewii</i>	Possible tick-borne relapsing fever, Asia	No culture available, laboratory animals	

<sup>a</sup> BHIS, brain heart infusion salt; HS, heart infusion plus serum; MKP, modified Kelly-Pettenkofer.

<sup>b</sup> See reference 136.

*Borrelia hermsii*, a combination of both methods is applicable: inoculation in mice followed by cultivation of isolated *Borrelia* in BSK medium (139) (Table 1).

The development of optimized culture medium for borreliae and axenic culture of spirochetes remains a challenge; thus, increasingly, new methods are appearing in the literature. Recently, the growth of *Leptospira* and *Borrelia* was shown to be supported by a versatile, axenic medium composed of Vero cell extracts (140).

### Mycobacteria

Mycobacteria are environmental organisms that can act as opportunistic pathogens, with a few notable exceptions that are host adapted and responsible for severe infections, including tuberculosis (*M. tuberculosis* complex), leprosy (*Mycobacterium leprae*), and Buruli ulcers (*Mycobacterium ulcerans*). Mycobacterial cul-

tures have long been regarded as requiring specialized laboratories. Recent data have indicated that mycobacteria are in no way particular regarding their manipulation in routine clinical microbiology laboratories. Concerning isolation, routine sheep blood medium sustains the isolation and growth of the vast majority of mycobacteria encountered in clinical microbiology laboratories, including *M. tuberculosis*, *Mycobacterium avium*, and *Mycobacterium intracellulare* (24, 141, 142), with the notable exception of *M. leprae*, which cannot be propagated outside animals (143) but can be cultured in the footpads of immunocompromised mice. In addition, sheep blood agar and sheep serum agar media have also been used to analyze *in vitro* susceptibility to antibiotics (144). Incubation temperature is another key factor for the successful culture of mycobacteria. Although 37°C is the standard incubation temperature used for most human pathogens, the ability of *M. leprae* to be cultured in the footpads of mice indicates that this

TABLE 2 Growth characteristics of obligate and opportunistic mycobacteria frequently encountered in clinical microbiology, including optimal temperatures<sup>a</sup>

Pathogen	Amoebal culture	Blood component requirement	Axenic culture growth	Nonconventional temp (°C)	Optimal growth in a microaerophilic atmosphere	Reference(s)
<b>Obligate</b>						
<i>M. tuberculosis</i> complex	+	+	+		+	24, 150
<i>M. leprae</i>	+		–	<30		151
<i>M. ulcerans</i>	+		+	30	+	334
<b>Opportunistic</b>						
<i>M. marinum</i>	+		+	<30		271
<i>M. xenopi</i>	+		+	45		149
<i>M. abscessus</i> complex	+		+			148
<i>M. massiliense</i>	+		+			148
<i>M. avium</i> complex	+		+			142
<i>M. tuberculosis</i>	NR		–	NR		153
<i>M. fortuitum</i> complex	+					148
<i>M. genavense</i>	NR	+	+		+	146
<i>M. haemophilum</i>		+	+	42		146
<i>M. mucogenicum</i> complex				30		
<i>M. aubagnense</i>				30		148
<i>M. phocaicum</i>				30		148
<i>M. porcinum</i> complex						148
<i>M. kansasii</i>	+					148
<i>M. simiae</i>	+					146
<i>M. malmoense</i>	+			24–42		148
<i>M. szulgai</i>	+			25–37		148

<sup>a</sup> NR, not reported.

species requires a low temperature of 28°C for growth. This finding is consistent with the clinical observation that leprosy develops in the nasal mucosa, superficial nerves, and the skin, which are body regions with temperatures of <37°C. Other pathogens, including *Mycobacterium marinum* and its derivative, *M. ulcerans*, as well as *M. haemophilum*, require a lower temperature of 30°C (145), and others, such as *Mycobacterium genavense* (146) and *Mycobacterium xenopi*, grow better at temperatures as high as 45°C. Similarly, the atmosphere of incubation warrants further evaluation. Mycobacteria have been reported to be aerobic; however, we recently observed that *M. tuberculosis* grew better in microaerophilia, which is defined as 2.5 to 5% oxygen tension, than in a conventional 5% CO<sub>2</sub> atmosphere (44). The fastidiousness of *M. tuberculosis* complex mycobacteria has further challenged growth detection techniques. In liquid medium, growth is routinely detected with automated instrumentation by significant changes in oxygen and carbon dioxide concentrations; in solid medium, colonies are routinely monitored by the naked eye, with difficulties in distinguishing colonies from inoculation debris. The natural autofluorescence of some mycobacteria can help in the detection of microcolonies. We observed 943- ± 51-µm-diameter colonies containing  $6.4 \times 10^5 \pm 3.5 \times 10^5$  mycobacteria by the naked eye, whereas by autofluorescence, we detected 103- ± 19-µm-diameter microcolonies containing  $7.9 \times 10^3 \pm 5.3 \times 10^3$  mycobacteria. Such microcolonies are identifiable by using the matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) technique, thus allowing culture-based diagnosis of mycobacterial infections as a routine task (147).

We also observed that most opportunistic mycobacterial pathogens are indeed amoeba-resistant organisms (148), as described comprehensively below. Interestingly, various amoebae are cul-

tured at various temperatures, which allows the modulation of the incubation temperature to isolate mycobacteria such as *M. xenopi* (149). We further showed that *M. tuberculosis* complex mycobacteria are also intra-amoebal organisms (150), as previously shown for the other two major obligate pathogens, *M. leprae* (151) and *M. ulcerans* (152). Therefore, almost all the opportunistic and obligate mycobacterial pathogens are, in fact, intra-amoebal mycobacteria, suggesting that this system could be used in cases of as-yet-uncultured opportunistic pathogens such as *Mycobacterium tuberculosis* (153) (Table 2).

Automatic systems using Middlebrook broth have revolutionized the routine culture of mycobacteria, yet parallel inoculation of solid media is still recommended to fill the gaps with automatic detection. Rapid progress in colony imaging, coupled with MALDI-TOF MS (147), could render broth culture obsolete. Solid media in miniaturized formats adapted to automated scanners could become the standard for culture and first-line antibiotic susceptibility testing (M. Drancourt, unpublished data). Axenic culture of as-yet-uncultured pathogens is another exciting challenge, as is the discovery of new opportunistic pathogens using the extended spectrum of axenic cell extract-containing media, such as that used for *Mycobacterium bovis* (120), and cell-based systems, including protozoa (150), offered by culturomics (154).

### Archaea

Phylogenetic classification based on the sequence of the 16S rRNA gene divide archaea into four phyla: the *Euryarchaeota* and *Crenarchaeota* (155–157), which include most cultivated archaea, as well as two new phyla, the *Nanoarchaeota* and *Korarchaeota*, which have a single cultivated species each. Methanogenic Archaea belonging to the phylum *Euryarchaeota* showed great adaptation to the human gut (158–164). *Euryarchaeota* and *Thaumarchaeota*






FIG 2 Archaeal species detected in or cultured from the human gut (97, 98, 159, 170, 181, 183, 185).

are parts of the skin microbiota (165–167) and the mucosa-associated microbiota of the oral and vaginal cavities (168). *Methanobrevibacter* species, *Methanosphaera* species, and *Sulfolobus* species sequences have been retrieved from coprolites dating from AD 180 to AD 600 (169). However, metagenomic studies, including the Human Microbiome Project, have most likely underestimated the diversity and the density of *Archaea* in microbiota (165) due to limitations of the currently used PCR primers and of archaeal DNA extraction protocols (170). Several studies have consistently observed an age-dependent increase in the prevalence and diversity of gut *Archaea* and methanogens (171–174). An increased prevalence of *Methanobrevibacter* spp. correlated, albeit nonsignificantly, with short-term and long-term carbohydrate ingestion (160), as was the case in anorexic patients (175), whereas the prevalence of *Nitrososphaera* spp. correlated, albeit nonsignificantly, with protein and amino acid ingestion (160). Methanogens in the oral cavity have been associated with periodontitis (176, 177); however, their role, if any, remains unknown.

Among the 20 currently described species among the human microbiota, 3 *Archaea* have been enriched but not obtained in pure culture. Halophilic *Halobacteriaceae* archaea were enriched in colonic mucosal biopsy specimens collected from one patient with inflammatory bowel disease (178). Fluorescence *in situ* hybridization (FISH) confirmed the presence of viable archaeal cells, but this archaeon has not been isolated in pure culture or deposited in public collections (178). Similarly, the use of meth-

anol as the substrate led to the enrichment in stool microbiota of “*Candidatus Methanomethylophilus alvus*” and “*Candidatus Methanomassiliicoccus intestinalis*,” a *Thermoplasmatales*-related lineage distantly related to its most closely related species, *Methanomassiliicoccus luminyensis* (179, 180) and *Aciduliprofundum boonei* (159, 174). *M. luminyensis* appears to be the sole cultured representative of a new, seventh order of methylotrophic methanogens (181). Finally, since the seminal isolation of uncharacterized methanogens 45 years ago (42), only 6 human-associated archaeal species have been isolated in pure culture and deposited into collections, all of which are strictly anaerobic. Methanogenic *Archaea* have also been isolated from the digestive tract (Fig. 2). After *Methanobrevibacter smithii* (97, 182), *Methanosphaera stadtmanae* (183) was isolated from the human gut, and *Methanobrevibacter oralis* was isolated from the oral cavity (184). In addition, our laboratory isolated *M. luminyensis* (179), *Methanobrevibacter arboriphilicus*, *Methanobrevibacter millerae*, and *M. oralis* from stool specimens (177). A versatile medium, combined with incubation at 37°C under an atmosphere of  $2 \times 10^5$  Pa consisting of 80% H<sub>2</sub> and 20% CO<sub>2</sub>, permitted the isolation and culture of these methanogens (98). This medium consisted of trace elements, including tungsten (185). Primary isolation was attempted by using the liquid formulation, with cultures being monitored by the CH<sub>4</sub> concentration, which was measured by chromatography, and by microscopic examination of the broth. The colonies were then obtained by subculturing of positive broth onto an agar-based

formulation of the same medium and by using the roll tube technique of Hungate (98, 186). Methanogens are autofluorescent at 420 nm and can be identified by using matrix-assisted laser desorption ionization–time of flight mass spectrometry (187). The availability of colonies allowed antibiotic susceptibility testing, which demonstrated the high natural resistance of *Archaea*, except against imidazole, its derivatives, and fusidic acid (188, 189), and genome sequencing (174, 180, 190). Several archaeal species remaining uncultured have been detected only by molecular tools (159, 161, 162, 165, 178, 191, 192). Thus far, only strictly anaerobic methanogenic *Archaea* have been isolated from humans. Specific strategies could be designed to enlarge the archaeal spectrum from human microbiota, such as halophilic or thermophilic *Archaea*. In addition, in the future, it will be interesting to determine the potential pathogenic roles of *Archaea* in clinical microbiology, particularly in polymicrobial abscesses. We suggest that large archaeal cultures applied to various human samples will partially fill the gap of “microbial dark matter” among the gut microbiota (193).

### INTRACELLULAR BACTERIAL CULTURE

Intracellular bacteria are responsible for human diseases with significant morbidity and mortality (194–196). *Rickettsia* spp. and *Orientia tsutsugamushi*, the causative agent of scrub typhus, have tropism for endothelial cells (195). *Coxiella burnetii*, which is the agent of Q fever, replicates in the acidic phagolysosomes of macrophages and monocytes (196). *Anaplasma phagocytophilum* and *Ehrlichia chaffeensis*, which cause tick-borne febrile illnesses, replicate preferentially in neutrophils and monocytes, respectively (195). *Chlamydia trachomatis* is the agent of trachoma, lymphogranuloma venereum (LGV), and other sexually transmitted diseases, and *Chlamydophila pneumoniae* and *Chlamydophila psittaci* can cause pneumonia. These cultures, which require suitable techniques, have been performed only in specialized laboratories. Some intracellular bacteria with high potential for infectivity require biosafety level 3 laboratories for their culture. At the beginning of the 20th century, the culture of intracellular bacteria developed considerably by adaptation of the systems used for virus isolation. For a long time, intracellular bacteria were isolated in embryonated eggs and/or with animal inoculation. Thus far, the successful isolation of intracellular bacteria has been based primarily on cell culture systems (197). Recently, the development of axenic medium led to a revival of intracellular pathogen culture (140, 198).

### Culture in Embryonated Eggs

In 1931, Goodpasture and colleagues described how fertilized chicken eggs could be used to cultivate some viruses (199, 200). Several years later, Cox injected intracellular bacteria into the yolk sacs of eggs and demonstrated the ability of bacteria to multiply extensively (201). The infections were confined to the yolk sacs and did not extend to adjacent embryonic tissues. For the growth curve of *C. burnetii* in yolk sacs, we observed a lag phase until the fourth day and a period of exponential growth, with maximal infection on the seventh day, followed by a rapid decrease (202, 203). Consequently, the strains were transferred from egg to egg on the third or fourth day, while the embryo was still living or during the 24 h following its death. The incubation temperature and the age of the eggs were critical. The optimal temperature was 35°C, and a higher or lower temperature was deleterious for the

survival of the embryo. Embryos aged 5 or 6 days were preferentially used; the yield was less elevated in older embryos, and younger embryos died prematurely. Virulence and infective titers were maintained through at least several dozen passages in the yolk sac, and this culture system provided higher infective titers than did mammalian tissues. The major inconvenience of this system is its high susceptibility to contamination and variations in its sensitivity according to egg susceptibility and host factors. Moreover, this procedure requires antibiotic-free-diet embryonated eggs from 5 to 8 days of age, which are often difficult to obtain. This culture system was extensively used to isolate and propagate *C. burnetii* and *Rickettsia* spp. as well as to study antibiotic susceptibility (204, 205). Currently, this culture system has been replaced by cell culture systems, which are more convenient to use. Today, only influenza viruses are routinely cultivated in eggs for vaccination production, and *Chlamydia* spp. and *L. pneumophila* are routinely cultivated for producing antigens for immunofluorescence assays.

### Animal Inoculation

The susceptibility of animals is dependent on the bacterial species from which the infection originated. Animals for which bacterial multiplication is more important and which present symptoms similar to those of humans are preferentially selected. Despite improvements in culture media, some bacteria remain uncultivable except in animal models, such as *M. leprae* and *T. pallidum*. This technique is expensive, time-consuming, and technically difficult and is applied only in specialized laboratories.

*M. leprae* differs from other mycobacteria in that this species cannot be cultured *in vitro*, despite many attempts. *M. leprae* propagation has been restricted to animal models, and several attempts have been undertaken in different animals with low body temperatures (206). First, *M. leprae* was propagated in mouse footpads, where  $10^6$  bacteria were harvested; however, no leprosy-like lesions were produced (207, 208). This yield could be increased by growing the bacteria in immunosuppressed mice (208). The animal most susceptible to *M. leprae* was a natural host for the bacterium, the nine-banded armadillo (*Dasypos novemcinctus*), which exhibited manifestations of leprosy comparable to those in humans (209, 210). In 1971, Kirchheimer et al. successfully cultured *M. leprae* in this exotic-looking house-cat-sized animal, which is present only on the American continents (209). Their low body temperature (32°C to 35°C) and long life span (12 to 15 years) make these animals preferred for propagating *M. leprae* (211). *Dasypos novemcinctus* is the only animal to develop regularly disseminated infections following intravenous inoculation; however, 30% of the infected animals do develop systematic infections. The organs of the reticuloendothelial system are the most affected (208), with bacterial concentrations reaching  $10^9$  to  $10^{11}$  *M. leprae* bacteria/g (211). The growth of *M. leprae* is extremely slow, with a doubling time of 14 days. Consequently, cultivation in armadillos requires a minimum of 18 months to obtain a sufficient number of bacilli.

*T. pallidum* culture is possible only after animal inoculation, which also remains the preferred method for isolating some species of *Borrelia* that are difficult to cultivate in cell culture or in artificial medium, as described above (134).

Inoculation of animals was also used for cultivating intracellular bacteria before the use of cell culture systems. Guinea pigs and mice are the preferred animals for *C. burnetii* and *Rickettsia* (196, 212). Moreover, some bacteria have been isolated from animals




FIG 3 Amoeba culturing methods for recovering amoeba-resisting microorganisms (ARMs). On the left, the method is performed by using laboratory axenic amoebal strains for recovering ARMs from diverse samples. On the right, the amoebae are wild species isolated from the samples, and the ARMs are recovered after amoebal isolation. The circles represent agar plates coated with bacteria, the line is the inoculation point of the sample, and the squiggles represent the growth of the amoebae, following a migration front. BCYE, buffered charcoal-yeast extract.

before being isolated by using cell culture systems. *Rickettsia felis* from fleas was propagated in male Sprague rats before cell culture (213). Similarly, "*Candidatus* Neoehrlichia mikurensis," which was first described in *Rattus norvegicus* rats and in *Ixodes ovatus* ticks, was cultured successfully in rats after intraperitoneal inoculation but has not yet been isolated in cell culture (214). Two major inconveniences of animal inoculation for culture is cross-contamination between infected and uninfected animals and low reproducibility. However, animal models are still useful when attempting to isolate intracellular bacteria from specimens contaminated with other bacteria and when removing contaminated mycoplasmas or microsporidia from cell cultures of intracellular bacteria (215, 216).

### Coculture with Amoebae

**History.** Some bacterial species are capable of resisting digestion after internalization by free-living amoebae and apply this amoeba-resisting property as a survival strategy in nonfavorable environments. These amoeba-resisting microorganisms (ARMs) consist of bacteria that belong to various phylogenetic clades dispersed throughout the prokaryotic tree (217), and some are human pathogens.

T. J. Rowbotham was a pioneer in the isolation of ARMs (218), using an amoebal enrichment method which allowed the isolation of *L. pneumophila* and other nonculturable, protozoanotic,

Gram-negative bacilli, called "*Legionella*-like amoebal pathogens" (LLAPs), from diverse environmental and clinical origins (218–220). Other investigations were performed to investigate the relationship between *Legionellae* species and other protozoa, primarily the ciliate *Tetrahymena* sp., in which *L. pneumophila* is able to survive and acquire high-virulence factors (221, 222).

The investigation of ARMs continued and resulted in the isolation of other microbial types, such as several *Mycobacterium* species (223, 224) and *Chlamydiales* or *Chlamydia*-like species (225). Several viruses were also isolated by using amoebae as culture tools, such as the giant amoeba-associated *Mimiviridae* (226) and their occasionally associated Sputnik virophages (227), *Marseilleviridae* (228), and, more recently, *Pandoravirus* (229).

Notably, protozoa have also been used in the past to isolate and/or to analyze the pathogenicity of strains of bacteria such as *Pseudomonas aeruginosa* (230, 231) and *Cryptococcus neoformans* (232, 233).

**Methods.** Two types of strategies have been used to isolate these ARMs (Fig. 3).

(i) **Coculture with amoebae.** The most commonly used method for the isolation of ARMs consists of inoculating samples onto a monolayer of amoebae, usually of the genus *Acanthamoeba*. This method has been largely used and described for isolating bacteria and even giant viruses (234, 235).

TABLE 3 Protists associated with amoeba-resisting microorganisms

Clade	Genus and species	Used for cocultivation and culture	Isolated with ARM(s)
Amoeba	<i>Acanthamoeba</i> sp.	Yes ( <i>Babela massiliensis</i> , etc.)	Yes ( <i>Parachlamydia acanthamoeba</i> , <i>Protochlamydia acanthamoeba</i> )
	<i>Acanthamoeba polyphaga</i>	Yes	Yes
	<i>Acanthamoeba castellanii</i>	Yes	Yes
	<i>Acanthamoeba comandoni</i>		Yes
	<i>Echinamoeba</i> sp.		Yes
	<i>Hartmanella vermiformis</i>	Yes	Yes ( <i>Neochlamydia hartmanella</i> )
	<i>Naegleria</i> sp.		Yes ( <i>Protochlamydia naeglerophila</i> )
	<i>Naegleria fowleri</i>	Yes	
	<i>Naegleria fultoni</i>		Yes
	<i>Naegleria australiensis</i>		Yes ( <i>Legionella</i> sp.)
	<i>Sacchamoeba</i> sp.	Yes	
	<i>Sacchamoeba lacustris</i>		Yes ( <i>Metachlamydia lacustris</i> )
	<i>Vannella</i> sp.		Yes (“ <i>Candidatus Mesochlamydia elodeae</i> ”)
	<i>Dictyostelium discoideum</i>	Yes	
<i>Vahlkampfia</i> sp.		Yes	
Ciliate	<i>Tetrahymena</i> sp.	Yes	
	<i>Tetrahymena hyperangularis</i>	Yes ( <i>Legionella</i> sp.)	
	<i>Tetrahymena tropicalis</i>	Yes ( <i>Legionella</i> sp.)	
	<i>Tetrahymena pyriformis</i>	Yes ( <i>Legionella</i> sp.)	
	<i>Paramecium bursaria</i>	Yes	
Flagellate	<i>Cafeteria roenbergensis</i>	Yes	
	<i>Trychonympha</i> sp.		Yes ( <i>Endomicrobia</i> )
	<i>Pyronympha</i> sp.		Yes ( <i>Endomicrobia</i> )

(ii) **Isolation of wild amoebae with their symbionts.** The second strategy consists of isolating the amoebae present in the sample by using culture on nonnutrient agar layered with a bacterium used as food (usually *Escherichia coli* or *Enterobacter* sp.). After isolation, the amoebae are analyzed for association with eventual ARMs. This method is efficient in isolating strict ARMs (236, 237).

(iii) **Protozoa used for ARM culture.** The amoebal species used for isolating ARMs are commonly *Acanthamoeba*, although other species have also been found to harbor ARMs. Amoebae and protists from other clades, which are presented in Table 3, have been found to be involved in symbiotic or parasitic associations with bacterial and/or viral ARMs.

**Results.** Bacteria from many different clades have been isolated from and/or associated with protozoa (217).

(i) **Alphaproteobacteria.** The species *Bartonella rattaustaliani* and *Rhizobium radiobacter* were shown to survive in *Acanthamoeba polyphaga* (238). *Bradyrhizobium* sp. or *Methylobacterium* sp. strains were found by using an amoebal coculture with *A. polyphaga* (235) and *Acanthamoeba castellanii* (223) and had a pathogenic effect on the amoebae (235, 239). Bacteria of the genera *Bosea* and *Afpia* have frequently been isolated from *Acanthamoeba* sp. in hospital networks and could possibly be related to human pathogenicity (219, 231, 235–238).

The species *Sphingomonas koreensis* was found to be associated with *Vanella* sp. In this case, the amoebae were also harboring a new genus of *Chlamydia*-like bacterium, called “*Candidatus Mesochlamydia elodeae*,” pathogenic for *Vanella* sp. and maintained in culture in another amoebal species, *Sacchamoeba lacustris* (240).

*Rickettsia bellii* was found to enter and remain stable for 6 weeks within the species *A. polyphaga*. Coinfection with *L. pneumophila* shows that both bacteria colocalize in the vacuoles of the

amoebae, and together with the observation of sequences similar to those of *L. pneumophila* and *Protochlamydia amoebophila* in the genome of *R. bellii*, this feature suggests communication and gene exchanges between bacteria inside the amoeba. Moreover, *R. bellii* has the ability to process gene exchange by conjugation with sexual pili (241).

The bacterium *Odyssella thessalonicensis* is a new, strictly intra-amoebal genus of the *Alphaproteobacteria*, which was isolated from environmental water samples and *A. polyphaga*.

(ii) **Betaproteobacteria.** Several *Betaproteobacteria* have been found to be associated with *Acanthamoeba* sp., for example, *Burkholderia* sp., *Delftia* sp., and *Acidovorax* sp. strains isolated from environmental samples (235, 242).

(iii) **Gammaproteobacteria.** Two species of the genus *Stenotrophomonas* were isolated by using coculture, *S. acidaminiphila* (242) and *S. maltophilia* (235). *S. maltophilia* was also found in association with *Dictyostelium discoideum*, causing infection, invasion, and growth inside the amoeba (243). More recently, two bacterial strains related to the *Stenotrophomonas maltophilia* complex were isolated from two different amoebae, *Acanthamoeba* sp. and *Naegleria* sp. Both amoebae were recovered and infected by the endosymbiont. These bacteria are pathogenic for the amoebae, and coculture leads systematically to the lysis of the amoebae (244). The genus *Aeromonas* has been associated with *Acanthamoeba* sp. (235, 242), has the capacity to multiply in the amoeba, and has cytopathic effects. The species *Aeromonas hydrophila* was found to interact actively with *A. castellanii* and to be able to survive within cysts (245, 246).

Some *Enterobacteriaceae* are also cultivable in several amoeba species. One study focusing on environmental water samples led to the isolation of several strains of *Acanthamoeba*-resisting *Enter-*

obacteriaceae, which are able to multiply within the amoeba but are nonpathogenic, including *Klebsiella* sp., *Enterobacter* sp., *Escherichia coli*, *Morganella morgani*, *Pantoea* sp., *Providentia* sp., and *Serratia* sp., etc. (235, 247); *Yersinia pseudotuberculosis*, *Salmonella enterica* serovar Typhimurium, and *Klebsiella pneumoniae* are able to infect the amoeba *D. discoideum* (243), and some strains of *Enterobacter aerogenes* and *E. coli* also multiplied within *A. castellanii* and survived within cysts (246, 248).

Some *Acinetobacter* species were found in coculture with *A. castellanii* and *A. polyphaga*, with cytopathic effects (235, 242). Additionally *Acinetobacter baumannii* was shown to interact actively with *A. castellanii* (249). For the genus *Pseudomonas*, environmental coculture studies with *Acanthamoeba* led to the isolation of *P. fluorescens* (242) and *P. aeruginosa* (223). *P. aeruginosa* also interacts with the amoeba *D. discoideum* (243). Moreover, this amoeba is now established as a culture model not only for *P. aeruginosa* but also for *L. pneumophila* and *Mycobacterium* sp. (232).

Historically, the genus *Legionella* was among the first to be associated with amoebae due to the ecology of these bacteria. *L. pneumophila* can multiply in not only *Acanthamoeba* sp. but also *Hartmanella* and *Dictyostelium* (243) and has the ability to stay in vacuoles of the ciliate *Tetrahymena*. Several other *Legionella* species have been found in association with different amoebae, and some of these species were new, such as the LLAPs *Legionella drozanskii*, *L. rowbothamii*, *L. fallonii* (250), and *L. drancourtii* (251). However, some other previously known *Legionella* species showed abilities to infect and multiply within amoebae (252). In 2004, an *Amoeba proteus* strain was isolated, which harbored a *Legionella*-like endosymbiont, named “*Candidatus Legionella jeonii*,” closely related to *Legionella* sp. (253).

Finally, other strictly intracellular *Gammaproteobacteria* have occasionally been shown to be associated with protozoa, such as *C. burnetii*, which is able to survive within *A. castellanii* (254), and *Francisella tularensis*, which is able to survive within cysts of *A. castellanii* (255).

(iv) **Epsilonproteobacteria.** Within the *Epsilonproteobacteria*, only *Campylobacter jejuni* has been demonstrated to have the capacity to multiply within protozoa, specifically *Acanthamoeba* sp. (256, 257).

(v) **Firmicutes.** Among the *Firmicutes* group, *Bacillus licheniformis* was shown to be pathogenically associated with *Naegleria fowleri*, with the effects depending on the bacterium/amoeba ratio (258). These different effects were further investigated by using several bacterial strains of the genus *Bacillus* and the amoebae *A. polyphaga* and *D. discoideum* (259).

Strain RN4220 of methicillin-sensitive *Staphylococcus aureus* was shown to be able to be internalized by *A. polyphaga* and to multiply within the amoeba (260), and the species *Staphylococcus pasteuri* and *S. pneumoniae* were isolated in a coculture with *Acanthamoeba* sp. (261). The pathogen *Streptococcus suis* was studied for its pathogenesis and interactions with the amoeba *Dictyostelium discoideum* (262).

(vi) **Bacteroidetes.** *Flavobacterium johnsoniae*, *Flavobacterium succinicans*, and *Flexibacter canadensis* were isolated by amoebal coculture with *Acanthamoeba* sp. or as symbionts of *Acanthamoeba* sp. (261). The two periodontopathogenic species *Porphyromonas gingivalis* and *Prevotella intermedia* were able to enter and multiply within *A. castellanii* (263). Several species of *Chryseobacterium* were isolated by coculture with *Acanthamoeba* sp. (235,

242), and two strains were described as new species: *Chryseobacterium massiliae* (239) and *C. massiliensis* (235). Other *Proteobacteria* representing new species or genera were isolated for the first time by amoebal coculture: *Cytophaga massiliensis* (235), “*Candidatus Amoebinatus massiliae*” (239), and “*Candidatus Amoebophilus asiaticus*” (264).

(vii) **Actinobacteria.** Several *Microbacterium* species and other *Actinobacteria*, such as *Rhodococcus equi* and *Rhodococcus erythropolis* (235, 242, 261), have been isolated by coculture with *Acanthamoeba* sp. The primary group of *Actinobacteria* studied for their interactions with protozoa is *Mycobacterium*. Indeed, many rapidly growing mycobacteria were able to be isolated by coculture with *Acanthamoeba* sp. (223, 224, 235, 252) or as natural symbionts in amoebae isolated from contact lens storage cases (265). In 1997, it was demonstrated for the first time that *M. avium* could enter and multiply in vegetative forms and also survive in cysts of *Acanthamoeba* sp. (266, 267). In 2004, *D. discoideum* was demonstrated to be a good model for studying mycobacterial intracellular trafficking using *M. marinum* (268). One study investigated the ability of waterborne *Mycobacterium* to survive within *A. polyphaga* and demonstrated that these bacteria could enter and multiply in the vegetative form of the amoeba, survive in the cyst forms, and resist chlorine treatment while protected inside those cysts (142, 148, 149). Moreover, a link was made between the ability of *Mycobacterium* to survive and multiply within amoebae and the acquisition or enhancement of some virulence traits (269–272). Some pathogenic or slow-growing mycobacteria were also shown to be associated with amoebae, such as the *M. tuberculosis* complex (150) and the pathogenic *M. ulcerans* (152). Another feature of the interactions between *Mycobacterium* and amoebae, the presence of several functional cellulose-targeting genes, was also elucidated recently (150, 273, 274). Another study showed the presence of the *celA* gene, which codes for a cellulase able to degrade carboxymethylcellulose and microcrystalline cellulose, in *Legionella pneumophila* strain 130b (275). The presence of these cellulase genes in the genomes of amoeba-associated bacteria suggests that these proteins could facilitate the growth of these bacteria within amoebae.

(viii) **Chlamydia.** The association of *Chlamydiales* with amoebae was demonstrated in 1997 with *Chlamydia pneumoniae*, which was able to multiply in *A. castellanii* (276). Recently, *Chlamydomydia abortus* was shown to enter and survive within *A. castellanii* but without multiplying (277). Coculture with several amoebae led to the discovery of several new genera, and these findings have extended much of the order *Chlamydiales*. Indeed, since the discovery and description of the new genus *Parachlamydia* in *Acanthamoeba* sp. (278), many other bacteria have been isolated from amoebal cultures, including *Neochlamydia hartmanella* (237), *Protochlamydia amoebophila* (279), *Criblamydia sequanensis* (280), *Protochlamydia naeglerophila* (281), *Metachlamydia lacustris* (282), *Estrella lausanensis* (283), and “*Candidatus Mesochlamydia elodeae*” (240).

Some other *Parachlamydia*-related bacteria isolated in mammalian cells have demonstrated susceptibility to amoebae. *Simkania negevensis* was cultivated successfully in *A. polyphaga* (284, 285), and *Waddlia chondrophila* was cultivated in *A. castellanii*, which enabled antibiotic susceptibility testing (286).

(ix) **Endomicrobia.** The *Endomicrobia* group is represented by uncultivated bacteria within the candidate phylum termite group I (TG-1) (287, 288). These bacteria were demonstrated to be as-

sociated with termite gut flagellates, primarily the species *Trichonympha* and *Pyronympha*, and each of the flagellate species harbors phylogenetically distinct species of *Endomicrobia* (288, 289).

(x) **TM6 phylum.** The TM6 phylum is a putative bacterial phylum represented by the single draft genome of a putative bacterium, JCVI TM6SC1, which was obtained by single-cell genomics and from numerous environmental sequences (290). Amoebal coculture with *Acanthamoeba* sp. recently enabled the isolation of the first effective strain of this phylum, a bacterium that we named *Babela massiliensis*. This bacterium harbors genome features that show high levels of degradation in the cell division machinery, and these features are introduced phenotypically by multiplication in the amoeba that resembles budding, different from classical binary fission (I. Pagnier, N. Yutin, O. Croce, K. S. Makarova, Y. I. Wolf, S. Benamar, D. Raoult, E. V. Koonin, and B. La Scola, unpublished data).

**Use in clinical microbiology.** Some ARMs have already been implicated in human pathology, primarily *Mycobacterium* spp., *Legionella* spp., and some *Chlamydia* spp. and *Parachlamydia* spp. Amoebal culture and research into ARMs are alternative methods of clinical diagnosis. For example, some *Legionella* species were able to be recovered from clinical specimens only by using amoebal culture (291). Moreover, the first giant virus isolated from a patient sample was a member of the *Marseilleviridae*, called senegalvirus, which was isolated from a stool sample of an asymptomatic patient from Senegal (154, 292). Later, the first human virus of the *Mimiviridae*, LBA111, was isolated from a pulmonary sample (293). Finally, a last giant virus of the *Mimiviridae*, called Shan virus, was isolated from a stool sample of a patient presenting with pulmonary disease (294). Amoebal culture could be useful for clinical diagnosis, primarily to target strictly intracellular ARMs, such as *Chlamydiales* or *Parachlamydiales* species. For example, the species *Protochlamydia naeglerophila*, which was isolated as a symbiont of the amoeba *Naegleria* sp., was found in a pathological sample of a patient with pneumonia by using molecular methods (281), and the species *Waddlia chondrophila* was shown to be able to survive and multiply within human macrophages, suggesting possible implications for human pathology (295, 296).

**Perspectives.** Culture of microorganisms with protozoa has facilitated several important steps in the comprehension of the microbiological world, and the relationships between protozoa and bacteria were able to be studied more deeply. Amoebal coculture led to the discovery of many new microorganisms, particularly new species such as *L. drozanskii*, *L. rowbothami*, *L. fallonii* (250), and *L. drancourtii* (251). New genera (*Chlamydia*- and *Parachlamydia*-related microorganisms) (282, 283) and new phyla (*Babela massiliensis*) (Pagnier et al., unpublished) or life domains (all amoeba-associated giant viruses) have also been recovered by amoebal coculture. The example of the isolation of *Babela massiliensis* (CSUR P554; GenBank accession number GQ495224 for 16S rRNA) is a good illustration of the increasing importance of microbial culture (Pagnier et al., unpublished). Indeed, many metagenomic approaches led to the discovery of entire unknown groups of microorganisms, and deeper study of these groups has been limited by the nonavailability of real bacterial strains. The use of coculture with amoebae allowed the recovery of a representative member of the putative TM6 phylum, and this finding will lead to other studies elucidating the intracellular way of life of the bacterium. The principle of isolation by coculture can be transferred to other types of protozoa, which could have other host-

microorganism spectra. Indeed, culture assays have already been performed with the axenized protists *Vermamoeba vermiformis*, *Dictyostelium discoideum*, *Tetrahymena hyperangularis*, and *Colpoda steinii*. Recently, a high-throughput method was developed by using the amoeba *Acanthamoeba* sp. to isolate giant viruses from >1,000 samples (297) by observation of a lysis plaque on an amoebal monolayer resting on an agar plate (297). Using other protists, lysis due to ARMs can be observed by flow cytometry. These methods have already led to the isolation of new microbial species, such as *Rubidus massiliensis* (CSUR P942; GenBank accession number HG726047 for 16S rRNA), a new *Parachlamydia*-related bacterium, and a new giant virus, associated with *Hartmannella vermiformis*.

## Cell Culture

Currently, the most common method for cultivating and isolating intracellular bacteria from clinical samples is cell culture. Two different strategies can be used. First, culture conditions can be standardized to allow the efficient growth of a broad range of bacteria. The second strategy consists of the specific isolation of an already known bacterium with specific adapted culture conditions for bacterial growth optimization. In fact, the type of cells and culture medium used should be adapted specifically, depending on the bacterium being cultivated. The susceptibility of bacteria to different cells lines varies according to their cell tropisms and optimal growth temperatures. Several eukaryotic cell lines can be used, including mammalian and arthropod cell lines. Two types of cells may be used: (i) cells cohering with each other, forming a cell monolayer, and (ii) cells circulating in suspension.

The temperature and atmosphere of incubation are critical and should be adapted. This culture strategy should also be used in the genomic and proteomic era, which requires a large amount of bacteria for large-scale investigations and for antigen production for diagnostic testing. Cell culture systems have also been used to evaluate the antibiotic susceptibility of intracellular bacteria by a plaque assay and a dye uptake assay (298, 299) or with a combination of culture and a PCR assay (5).

**Cell lines grown at 37°C.** Mammalian cells developing at 37°C are the most often used cells. *C. burnetii* can be grown with a doubling time of 20 h in mouse macrophage-like (P388D1 and J774), murine fibroblast (L929), and kidney epithelial (Vero) cell lines (196, 300–302). Human embryonic lung (HEL) fibroblasts have been preferentially used for routine culture because of their easy maintenance and high level of susceptibility to *C. burnetii* infection. The observed cytopathic effects were the occurrence of large vacuoles in the cytoplasm. *C. burnetii* infection does not destroy host cells, allowing the maintenance of *C. burnetii* for several months in persistent culture (196, 303).

Culture of *Rickettsia* was first performed by using a primary monocyte cell culture (304). In the 1980s, Vero and L929 cells were used, allowing better and more rapid isolation of rickettsiae than with HEL and MRC5 (human fetal lung fibroblast) cells (305). In fact, *Rickettsia conorii* presented higher multiplication rates in L929 cells than in Vero or 3T3 cells (306). Most of the *Rickettsiae* belonging to the spotted fever group can polymerize actin from cells, to move into the nucleus of the host cell and promote cell-to-cell spreading, which generates rapid cytopathic effects and rapid plaque formation at an optimal growth temperature of 32°C (307). The optimal growth temperature of *Rickettsia* from the typhus group is 35°C. The bacteria invade adjacent cells

only when their multiplication and accumulation in the cytoplasm cause host cell lysis. Consequently, cytopathic effects were less prominent, and the plaques formed were small (307).

L929 cells have been used for culturing *O. tsutsugamushi*, which grew slowly, and 1,000 bacteria were required to invoke cell disruption and propagation in adjacent cells (308). Consequently, a long incubation period is required, which involves difficulties in maintaining the integrity of the cell monolayer and contamination-free medium.

The establishment of *T. whipplei* in culture was reported in 2000, using HEL cells (309), and the bacterium was then cultured from various clinical samples (310). Antibiotics were added to the culture medium to cultivate samples that were naturally contaminated, such as duodenal biopsy specimens or stool specimens (311, 312). The growth of *T. whipplei* was also observed in MRC-5 (313) and HeLa (314) cells.

DH82, which is a continuous canine macrophage cell line (315), is usually used to isolate *E. chaffeensis* and *Ehrlichia canis* (316). However, several other cell lines can be employed, such as mouse embryo, Vero, Buffalo green monkey kidney (BGMK), HEL, HeLa, and L929 cells (315, 317, 318). *E. chaffeensis* induced cytopathic effects on mouse embryo, L929, HEL, and Vero cells and caused macroscopic plaque formation in L929 and mouse embryo cells (318) and microscopic plaque formation in Vero cells (317). *Anaplasma phagocytophilum* has been cultured routinely and with a rapid development of cytopathic effects (319) in HL-60, a human promyelocytic leukemia cell line that grows in suspension culture (320). This cell line was highly susceptible to *A. phagocytophilum* infection. Fresh blood or the leukocyte fraction of EDTA-blood can be inoculated into a 25-cm<sup>2</sup> flask containing a density of  $2 \times 10^5$  cells/ml. However, the ability of *A. phagocytophilum* to establish *in vivo* infection successfully decreased considerably when it was continually maintained in cell culture (321).

Several mammalian cell lines have been used to propagate *Chlamydia* spp., including mouse fibroblast (McCoy and L cells), human cervical carcinoma (HeLa 229), human laryngeal carcinoma (HEp-2), human epithelial (HL), BGMK, and Vero (322) cell lines. To permit the entry of *Chlamydia* spp. into host cells and the creation of a favorable intracellular environment, several steps in the process are critical for the success of *Chlamydia* species culture (323, 324). A centrifugation step and/or the addition of polycationic stabilizing molecules to overcome the repellent forces between the membrane of the host cell and the bacteria was required, except for *C. psittaci* and the LGV agent. Cycloheximide, which is a selective inhibitor of eukaryotic protein and nucleic acid synthesis, was added to reduce the competition for nutrients between host cells and bacteria, thus enhancing the growth of *Chlamydia* (325). The cultures were incubated for 48 to 72 h at 35°C. McCoy and HeLa 229 cells are the cell lines most commonly used for *C. trachomatis* culture (322, 324), and HL and HEp-2 cells seem to be more sensitive for the recovery of *C. pneumoniae* (323, 326). The cytopathic effect occurs as small, rounded intracytoplasmic inclusions, visualized by immunostaining of cell monolayers.

**Cell lines grown at 28°C.** Some bacteria require temperatures of <37°C to grow; consequently, the use of cell lines specifically tailored to lower temperatures is required, such as amphibian, tick, mosquito, and fish cell lines. These cell lines have been commonly used for arbovirus culture and allow the isolation of intracellular bacteria, such as *Rickettsia felis*. The first culture of *R. felis*,

which was performed with Vero and L929 cells after incubation at 37°C, was in reality contamination of the culture by *Rickettsia typhi* (213, 327, 328). Thus, the culture of *R. felis* has been credited to Raoult et al. (40), who cultivated this bacterium with success in an amphibian cell line derived from *Xenopus laevis* (XTC2) after 6 days of incubation at 28°C. The bacterium also grows slowly on Vero cells at 28°C and 32°C (40, 329). The growth of *R. felis* in mammalian cell lines is inconstant but was improved by the addition of tryptose phosphate broth in culture media, which seems to be a critical component based on its involvement in the electron transport chain of the Krebs cycle (330). More recently, growth of *R. felis* in *Drosophila melanogaster* S2 cells was reported, with a cell infection rate of 100% after 19 days of incubation at 25°C (331). Other arthropod-borne bacteria, such as *Diplorickettsia massiliensis* (332), *Wolbachia* sp., and *Bartonella bacilliformis* (40), as well as other bacteria such as *Piscirickettsia salmonis* (333) and *M. ulcerans* (334) can also be cultivated more effectively by using this cell line.

Approximately 40 different tick cell lines are available, primarily from ixodid rather than argasid tick species (335). These cells have the advantage of partially reproducing the natural environment of tick-borne pathogens. Most tick cells grow at incubation temperatures of between 28 and 34°C, and acidic or alkaline pH conditions vary according to the cell line. Cells from ticks divide slowly, require up to 1 month between passages, and are generally not strongly adherent, generating partial monolayers or a suspension culture. Tick cell lines have been used successfully for the growth of *A. phagocytophilum*, *Anaplasma marginale*, *Ehrlichia canis*, *Ehrlichia ruminantium*, *Borrelia* spp., *Rickettsia* spp., *Bartonella* spp., and *C. burnetii* (335–340) as well as for the isolation of unknown bacteria, such as a new *Anaplasma* sp. (341), *Borrelia lonestari* (342), and *Rickettsia monacensis* (343). Mosquito cell lines are permissive to multiple arthropod-borne infections and offer the advantage of being easier to culture than tick cell lines. Mosquito cell lines can be passaged in 1 week and grown at room temperature under an ambient atmosphere and have the potential to develop high bacterial titers, and infection is stable in the cells for >40 passages (339). In particular, *Anopheles gambiae* (Sua5B) and *Aedes albopictus* (Aa23 or C6/36) cell lines have been used to grow *R. felis*, *R. montanensis*, *R. peacockii*, and *R. typhi* as well as several strains of the bacterial symbiont *Wolbachia* (37, 339, 344–349).

Few assays have been performed to grow fish-pathogenic bacteria in a fish cell line at temperatures between 21°C and 30°C. *Mycobacterium marinum* was cultivated successfully in a carp monocyte cell line at 28°C (350), and *Piscirickettsia salmonis* was cultivated in a Chinook salmon cell line (351) (Table 4).

**Specific devices (shell vial).** The shell vial assay is currently the method used in specialized laboratories to isolate fastidious bacteria from clinical samples (Fig. 4). This technique was adapted to bacterial culture in 1989 (352) from a centrifugation-cell microculture system, which was described in 1976 and used for virus isolation (353). The principles of this technique are based on the inoculation of clinical specimens by low-speed centrifugation on confluent cell monolayers seeded onto 1-cm<sup>2</sup>-round coverslips and incubated with 1 ml of culture medium in a shell vial. The centrifugation step is critical because this step enhances the attachment and penetration of the bacteria in cells (354). The sensitivity of this cell culture technique is increased by the small surface area of the coverslip, which contains cells that enhance the

TABLE 4 The most susceptible cells line used for the culture of intracellular bacteria<sup>a</sup>

Bacterium	Cell line(s) (culture temp [°C])		Fish and amphibian	Reference(s)
	Mammalian	Arthropod		
<i>C. burnetii</i>	HEL, Vero (35)	<i>Ixodes scapularis</i> cell line-IDE8 (34)		196, 336
Spotted fever group <i>Rickettsia</i>	L929, Vero (32)	<i>Dermacentor</i> sp. cell lines DAE3 and DALBE3 (34); <i>Ixodes scapularis</i> cell line ISE6 (34); <i>Aedes albopictus</i> cell lines Aa23, AeAl2, C7/10, and C6/36 (22–32); <i>Anopheles gambiae</i> cell line Sua5B (22–25)		212, 305, 306, 335, 338, 344, 348
Typhus group <i>Rickettsia</i> <i>Rickettsia felis</i>	L929, Vero (35) Vero (32)	<i>Aedes albopictus</i> cell line AeAl2 (28) <i>Ixodes scapularis</i> cell line ISE6 (32), <i>Aedes albopictus</i> cell lines Aa23 and C6/36 (22–25), <i>Anopheles gambiae</i> cell line Sua5B (22–25)	XTC (28)	212, 349 40, 329, 337, 338, 340, 345
<i>Orientia tsutsugamushi</i>	L929 (32)			308
<i>Anaplasma phagocytophilum</i>	HL60 (37)	<i>Ixodes scapularis</i> cell lines ISE6 and IDE8 (34)		319–321, 335, 341
<i>Ehrlichia chaffeensis</i>	DH82 (37)	<i>Ixodes scapularis</i> cell line ISE6 (34)		315, 316, 335
<i>Ehrlichia canis</i>	DH82 (37)	<i>Ixodes scapularis</i> cell line ISE6/IDE8 (34) <i>Ixodes ricinus</i> cell line IRE/CTVM18 (34)		315, 316, 318, 335
<i>Wolbachia pipientis</i>	HEL (28 and 37)	<i>Aedes albopictus</i> cell lines Aa23 and C6/36 (26–28)		37, 346, 347
<i>Tropheryma whipplei</i>	MRC5, HEL (35)			309, 310
<i>Chlamydia trachomatis</i>	McCoy, HeLa 229 (35)			322, 324
<i>Chlamydia pneumoniae</i>	HL, HEp-2 (35)			323, 326

<sup>a</sup> Shown are the most susceptible cell lines from mammals, arthropods, fish and amphibians used for culturing of intracellular bacteria, including *C. burnetii*, *Rickettsia* spp., *Ehrlichia* spp., *T. whipplei*, *Chlamydia* spp., and *Anaplasma* spp.

ratio of the number of intracellular bacteria to the number of cells and that allow more efficient recovery. Moreover, the cell type, length, atmosphere, and incubation temperature can be optimized according to the suspected pathogen. Different protocols can be used for the specific isolation of *Rickettsia* spp., *Bartonella* spp., *C. burnetii*, or *Tropheryma whipplei*, and one protocol, which is called “JNSP,” is based on the French abbreviation of the sentence “*Je ne sais pas*,” which means “I do not know” what I am growing, for unspecific research into other intracellular bacteria (Fig. 4). HEL fibroblasts are used because of their high level of susceptibility to intracellular bacterial infection and their ease of maintenance. To avoid bacterial contamination, antibiotics with no activity against the bacteria of interest can be added. The growth of bacteria is detected by observation of cytopathic effect; acridine orange, Giemsa, and/or Gimenez staining; or immunofluorescence revelation using the patient’s serum or sera from immune animals as the primary antibody (197). Definitive identification of the bacteria is performed by PCR. This technique is used routinely in our laboratory and permits the successful isolation of spotted fever group *Rickettsia* (355), *Rickettsia prowazekii* (356), *C. burnetii* (357), *C. trachomatis* (358), and fastidious bacteria such as *Bartonella* sp. (48, 359), *F. tularensis* (360), *Mycobacterium* sp. (359, 361), *L. pneumophila* (362), *Brucella melitensis* (363), *Actinomyces* sp. (197), *Streptobacillus moniliformis* (364), and *Nocardia* sp. (197). The shell vial assay exhibits a low rate of success, but this success can be extremely valuable (197). This technique facilitated the establishment of *T. whipplei* from a cardiac valve of a patient with Whipple’s disease endocarditis in the context of JNSP protocols (309). In some cases, this technique is the only technique that allows microbiological diagnosis, and the shell vial system was also used for testing the antibiotic susceptibilities of intracellular bacteria (365, 366).

#### Axenic Culture Media for Intracellular Bacteria

Knowledge of pathogen physiology and the host cell-pathogen interaction and the use of new tools, such as genomic and tran-

scriptomic analyses, have enabled the study of metabolic pathways, enhancing the success of axenic cultivation (198, 367, 368). The establishment of axenic culture media could have significant effects on the study of their pathogenicity, virulence, and antibiotic susceptibility and on the design of new diagnostic tools (140).

***Coxiella burnetii*.** *Coxiella burnetii* has been described as being cultivable in an acellular chemically defined medium (11, 369, 370), a medium designed after a comprehensive analysis of the nutrient consumption of *C. burnetii*. First, genomic analysis identified three critical components for this complex *Coxiella* medium (CCM) to sustain the metabolic activity of the bacteria as well as 3 complex nutrient sources (Neopeptone, fetal bovine serum, and RPMI cell culture medium) and a high concentration of chloride and citrate buffer, mimicking the acidic environment of phagosomes (370). A transcriptomic analysis resulted in the conception of ACCM (acidified citrate cysteine medium) enriched with cysteine and Casamino Acids that support the growth of *C. burnetii* by >3 log<sub>10</sub> units after 6 days of incubation in a microaerophilic atmosphere (11, 371). This medium was then optimized through the replacement of fetal bovine serum by methyl-β-cyclodextrin and was named ACCM-2; ACCM-2 sustained 4- to 5-log<sub>10</sub> growth of *C. burnetii* over 7 days with the addition of moderate shaking (372). Moreover, colonies were observed on ACCM-2 agarose (372). More recently, Singh et al. showed the exponential growth of *C. burnetii* in an empirical medium containing eukaryotic cell extracts (120). With the medium being refreshed every 2 days, low oxygen tension and the presence of small hydrophilic molecules and short peptides were critical for its growth. However, this medium harbors a neutral pH, suggesting that the growth of *C. burnetii* does not require acid activation of its metabolic pathways. The antigenicity and the virulent form (phase I) of *C. burnetii* were conserved, revealing the potential for this culture medium to be used for antigen and vaccine production. Furthermore, this medium permitted the successful isolation of *C. burnetii* from pathological samples.






FIG 4 Shell vial system protocols used for specific isolation of *Bartonella*, *Coxiella burnetii*, rickettsiae, or *T. whipplei* and for unspecific research into other intracellular bacteria according to JNSP protocols.

***Tropheryma whipplei*.** Culture of *T. whipplei* permitted the obtaining of the complete genomes of two different strains of *T. whipplei* (7, 313). Genomic analysis revealed a reduced genome size (0.9 Mb) and a specific metabolic deficiency. The genes coding for metabolic pathways for nine amino acids were entirely missing, and the pathways of glutamate and phenylalanine synthesis were nonfunctional (13). An axenic medium compensating for these deficiencies was designed based on these genomic analyses (13, 368). This medium consisted of cell culture medium that provided the missing amino acids, supplemented with 10% fetal calf serum, 1% glutamine, and 1% human nonessential amino acids (13). This approach permitted the successful growth of *T. whipplei* from a great variety of clinical samples as well as antibiotic susceptibility testing (4, 373). The development of an axenic medium permitted the culturing of isolates from sterile and non-sterile sources, such as saliva and stool samples, after a decontamination procedure with glutaraldehyde (312) or with filtration (374, 375).

***Chlamydia* species.** *C. trachomatis*, similar to other members of the *Chlamydiaceae* family, presents a biphasic developmental cycle, with important consequences for its metabolic activity and axenic growth. During their biphasic intracellular development cycle, the surviving infectious elementary bodies (EBs) extracellularly differentiate into reticulate bodies (RBs) after entry into the cytoplasm of the host cells, which multiply by binary fission. Two

recent studies demonstrated the ability of EBs to conduct metabolic activity outside the cytoplasm of host cells (198, 376). The development of a host cell-free medium was based on analysis of the *C. trachomatis* genome. A reduced genome (1.04 Mb) and the several missing enzymes and entire metabolic pathways suggested that *C. trachomatis* uses nutrients from host cells for its growth (377). The axenic medium supporting the metabolic activity of *C. trachomatis* consisted of a novel intracellular phosphate buffer and an ion concentration mimicking the composition of the eukaryotic cytoplasm (14). Incubation in a microaerophilic atmosphere and an energy source were critical for the metabolic activity of *C. trachomatis*. EBs have been historically described as metabolically dormant; however, in cell-free media, high levels of metabolic and biosynthetic activity were observed for both EBs and RBs, although the EBs primarily used glucose-6-phosphate, and the RBs used ATP as an energy source. This axenic medium, with further modifications, promises to support the replication of *C. trachomatis* and the study of the metabolism and physiology of *Chlamydiae*.

**Empirical broad-spectrum medium.** Singh et al. developed an axenic liquid medium based on an extract of eukaryotic cells, allowing the growth of a broad spectrum of bacteria. The eukaryotic cell extract-based universal empirical medium, which was tested for culturing of *C. burnetii* as a proof of concept, supported the growth of other fastidious bacteria and putative bacterial bioter-

rorism agents (120). Rapid growth (<72 h) was observed for *T. whipplei*, *Yersinia pestis*, *Vibrio cholerae*, *Bacillus anthracis*, *Shigella dysenteriae*, *Brucella melitensis*, *Bordetella pertussis*, and *Bartonella henselae*. *F. tularensis* and *M. bovis* were able to grow on this medium in 20 and 8 days, respectively, and *Campylobacter* spp. were able to grow in 5 days under microaerophilic conditions. In addition, this medium was the first to permit the growth of two spirochetes belonging to different genera, *B. crocidurae* and *L. interrogans*, with delays of 14 and 4 days, respectively. However, two limitations of this medium are its inability to sustain the growth of other intracellular bacteria, including *Rickettsia* and *Legionella* species, and its variability, which is caused by the use of uncharacterized biological products. The primary advantage of this empirical medium is its versatility; thus, this medium can be used for many applications, including the isolation and culture of unknown fastidious bacteria from clinical samples, which encourages its use as a replacement for cell-based culture systems. Moreover, this medium offers promising perspectives for culturing other intracellular fastidious bacteria by testing variations in temperature, atmosphere of incubation, and supplementation with nutrients and growth factors required by the bacteria.

**Future challenges.** We have reviewed older and more current approaches used to cultivate intracellular bacteria. No single approach exists. Older techniques, such as animal inoculation, are still used to propagate some bacteria and to isolate new bacterial species, such as “*Candidatus* Neoehrlichia mikurensis.” Cell culture permits the growth of a large number of intracellular bacteria; however, in some cases, cell culture must be more specifically adapted to particular species, mimicking their natural environment to optimize their growth. Future prospects will be based largely on the development of axenic media, facilitating genetic manipulation, and on an understanding of microbial ecology and the pathogenicity of fastidious bacteria. Axenic growth of the historically “uncultivable” *T. pallidum* and *M. leprae* has remained a large challenge for a century. The success of axenic growth of *C. burnetii* and *T. whipplei*, as well as the design of axenic media for the growth of *Rickettsia*, *Anaplasma*, *Ehrlichia*, *Orientia*, and *Chlamydia*, should accelerate soon.

## CONCLUSION

Our laboratory (URMITE, Marseille, France), which was created *ex nihilo* in 1984 and which initially specialized in intracellular bacterial culture, has now extended its experience into many fields of clinical microbiology, tirelessly demonstrating the central role of pure culture in understanding infectious diseases. The shell vial procedure and intracellular culture have allowed us to culture 18 different species of *Rickettsia* and have facilitated participation in the description of 7 new bacterial species or subspecies (195, 378–383) and in the first culture of 4 new rickettsial species (40, 384–386). Interestingly, *Rickettsia felis* is now associated with acute febrile illness (387, 388) and with a vesicular fever called “yaaf” in Africa (389). Currently, we have cultured 41 different *T. whipplei* strains from diverse tissues and fluid (310, 312, 374, 375, 390, 391), playing a key role in the understanding of the clinical manifestations caused by this bacterium (194). Coculture with amoebae, which was performed in our laboratory, has allowed us to identify 139 different bacterial species from both clinical and environmental samples, including 10 new bacterial species (224, 235, 239, 251, 261, 392–396). In our laboratory, the great qualities of several “cultivators,” technicians, or researchers were identified

and recognized in the names of bacterial species to honor these qualities (i.e., *Rickettsia raoultii*, *Legionella drancourtii*, *Mycobacterium barrassiae*, *Afpia birgiae*, *Bosea vestrisii*, and *Bosea eneeae*, etc. [251, 384, 392, 396, 397]), as the names of other species acknowledge several “cultivators,” such as *Finegoldia magna*, *Murdochella asaccharolytica*, or *Gordonibacterium pamelaee* (398, 399).

Despite the spectacular advances in microbial culture in recent years, there are still unsatisfactory results remaining. A large part of anaerobic bacteria detected by molecular methods remain as yet uncultured. The optimization of transport time and the use of antioxidants will allow a dramatic increase of this repertoire. The development of axenic culture of spirochetes such as *T. pallidum* or *M. leprae* remains an important challenge in clinical microbiology.

Some bacteria have not yet been cultivated due only to the lack of investigators; *Rickettsia raoultii* was cultivated for the first time by Oleg Mediannikov, whereas we failed to culture this strain in the same laboratory for 8 years (384). The patience and energy required for the primary culture of a bacterium are often considerable. Culture is a complex and difficult art, in which the individual qualities of the scientist are not comparable with the individual qualities required by researchers using a more biochemically defined method.

## ACKNOWLEDGMENTS

We thank all the technicians and researchers working in our laboratory implicated in bacterial culture.

Michel Drancourt and Didier Raoult are coinventors of pending patents on the culture and subculture of *M. tuberculosis*, and Didier Raoult is coinventor of a pending patent on the culture of anaerobes and Vero cell extract medium. All these patents are owned by Aix Marseille University.

## REFERENCES

1. Brock T. 1999. Robert Koch: a life in medicine and bacteriology. American Society for Microbiology, Washington, DC.
2. Koch R. 1882. Die Ätiologie der Tuberkulose. Berl Klin Wochenschr 15:221–230.
3. Marshall BJ, Armstrong JA, McGeachie DB, Glancy RJ. 1985. Attempt to fulfil Koch's postulates for pyloric *Campylobacter*. Med J Aust 142: 436–439.
4. Boulos A, Rolain JM, Mallet MN, Raoult D. 2005. Molecular evaluation of antibiotic susceptibility of *Tropheryma whipplei* in axenic medium. J Antimicrob Chemother 55:178–181. <http://dx.doi.org/10.1093/jac/dkh524>.
5. Boulos A, Rolain JM, Raoult D. 2004. Antibiotic susceptibility of *Tropheryma whipplei* in MRC5 cells. Antimicrob Agents Chemother 48: 747–752. <http://dx.doi.org/10.1128/AAC.48.3.747-752.2004>.
6. Fournier PE, Drancourt M, Raoult D. 2007. Bacterial genome sequencing and its use in infectious diseases. Lancet Infect Dis 7:711–723. [http://dx.doi.org/10.1016/S1473-3099\(07\)70260-8](http://dx.doi.org/10.1016/S1473-3099(07)70260-8).
7. Raoult D, Ogata H, Audic S, Robert C, Suhre K, Drancourt M, Claverie JM. 2003. *Tropheryma whipplei* Twist: a human pathogenic Actinobacteria with a reduced genome. Genome Res 13:1800–1809.
8. Fournier PE, Drancourt M, Colson P, Rolain JM, La Scola B, Raoult D. 2013. Modern clinical microbiology: new challenges and solutions. Nat Rev Microbiol 11:574–585. <http://dx.doi.org/10.1038/nrmicro3068>.
9. Lagier JC, Million M, Hugon P, Armougom F, Raoult D. 2012. Human gut microbiota: repertoire and variations. Front Cell Infect Microbiol 2:136. <http://dx.doi.org/10.3389/fcimb.2012.00136>.
10. Kaerberlein T, Lewis K, Epstein SS. 2002. Isolating “uncultivable” microorganisms in pure culture in a simulated natural environment. Science 296:1127–1129. <http://dx.doi.org/10.1126/science.1070633>.
11. Omsland A, Cockrell DC, Howe D, Fischer ER, Virtaneva K, Sturdevant DE, Porcella SF, Heinzen RA. 2009. Host cell-free growth of the Q fever bacterium *Coxiella burnetii*. Proc Natl Acad Sci U S A 106:4430–4434. <http://dx.doi.org/10.1073/pnas.0812074106>.

12. Bollmann A, Lewis K, Epstein SS. 2007. Incubation of environmental samples in a diffusion chamber increases the diversity of recovered isolates. *Appl Environ Microbiol* 73:6386–6390. <http://dx.doi.org/10.1128/AEM.01309-07>.
13. Renesto P, Crapoulet N, Ogata H, La Scola B, Vestris G, Claverie JM, Raoult D. 2003. Genome-based design of a cell-free culture medium for *Tropheryma whipplei*. *Lancet* 362:447–449. [http://dx.doi.org/10.1016/S0140-6736\(03\)14071-8](http://dx.doi.org/10.1016/S0140-6736(03)14071-8).
14. Omsland A, Sager J, Nair V, Sturdevant DE, Hackstadt T. 2012. Developmental stage-specific metabolic and transcriptional activity of *Chlamydia trachomatis* in an axenic medium. *Proc Natl Acad Sci U S A* 109:19781–19785. <http://dx.doi.org/10.1073/pnas.1212831109>.
15. Lagier J-C, Hugon P, Khelaifia S, Fournier PE, La Scola B, Raoult D. 2015. The rebirth of culture in microbiology through the example of culturomics to study human gut microbiota. *Clin Microbiol Rev* 28:237–264. <http://dx.doi.org/10.1128/CMR.00014-14>.
16. Marmonier A. 2007. Diagnostic phénotypique, p 49–60. In Freney J, Renaud F, Leclercq R, Riegel P (ed), *Précis de bactériologie clinique*. ESKA, Paris, France.
17. Kilian M. 2007. *Haemophilus*, p 636–648. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), *Manual of clinical microbiology*, 9th ed. ASM Press, Washington, DC.
18. Loeffelholz MJ, Sanden GN. 2007. Bordetella, p 803–814. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), *Manual of clinical microbiology*, 9th ed. ASM Press, Washington, DC.
19. Petri R. 1887. Über die Methoden der modernen Bakterienforschung. Richter, Hamburg, Germany.
20. Hitchens AP, Leikind MC. 1939. The introduction of agar-agar into bacteriology. *J Bacteriol* 37:485–493.
21. Pfyffer GE. 2007. Mycobacterium: general characteristics, laboratory detection, and staining procedures, p 543–572. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), *Manual of clinical microbiology*, 9th ed. ASM Press, Washington, DC.
22. Funke G, Bernard A. 2007. Coryneform gram-positive rods, p 485–514. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), *Manual of clinical microbiology*, 9th ed. ASM Press, Washington, DC.
23. Sonnenwirth AC. 1972. Evolution of an anaerobic methodology. *Am J Clin Nutr* 25:1295–1298.
24. Drancourt M, Carrieri P, Gevaudan MJ, Raoult D. 2003. Blood agar and *Mycobacterium tuberculosis*: the end of a dogma. *J Clin Microbiol* 41:1710–1711. <http://dx.doi.org/10.1128/JCM.41.4.1710-1711.2003>.
25. Drancourt M, Raoult D. 2007. Cost-effectiveness of blood agar for isolation of mycobacteria. *PLoS Negl Trop Dis* 1:e83. <http://dx.doi.org/10.1371/journal.pntd.0000083>.
26. Chapin KC, Lauderdale TL. 2007. Reagents, stains, and media: bacteriology, p 334–364. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), *Manual of clinical microbiology*, 9th ed. ASM Press, Washington, DC.
27. Subramanyam B, Sivaramakrishnan GN, Dusthacker A, Nagamiah S, Kumar V. 2012. Phage lysis as a substitute for antibiotics to detect *Mycobacterium tuberculosis* from sputum samples with the BACTEC MGIT 960 system. *Clin Microbiol Infect* 18:497–501. <http://dx.doi.org/10.1111/j.1469-0691.2011.03601.x>.
28. Le Chevallier MW, Cameron SC, McFeters GA. 1983. New medium for improved recovery of coliform bacteria from drinking water. *Appl Environ Microbiol* 45:484–492.
29. Kubica GP, Dye WE, Cohn ML, Middlebrook G. 1963. Sputum digestion and decontamination with N-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria. *Am Rev Respir Dis* 87:775–779.
30. Lloyd WJ, Broadhurst AV, Hall MJ, Andrews KJ, Barber WE, Wong-Kai-In P. 1988. Cyclohexane triones, novel membrane-active antibacterial agents. *Antimicrob Agents Chemother* 32:814–818. <http://dx.doi.org/10.1128/AAC.32.6.814>.
31. Ferroni A, Vu-Thien H, Lanotte P, Le Bourgeois M, Sermet-Gaudelus I, Fauroux B, Marchand S, Varaigne F, Berche P, Gaillard JL, Offredo C. 2006. Value of the chlorhexidine decontamination method for recovery of nontuberculous mycobacteria from sputum samples of patients with cystic fibrosis. *J Clin Microbiol* 44:2237–2239. <http://dx.doi.org/10.1128/JCM.00285-06>.
32. El Khechine A, Henry M, Raoult D, Drancourt M. 2009. Detection of *Mycobacterium tuberculosis* complex organisms in the stools of patients with pulmonary tuberculosis. *Microbiology* 155:2384–2389. <http://dx.doi.org/10.1099/mic.0.026484-0>.
33. Bonnave PE, Raoult D, Drancourt M. 2013. Gastric aspiration is not necessary for the diagnosis of pulmonary tuberculosis. *Eur J Clin Microbiol Infect Dis* 32:569–571. <http://dx.doi.org/10.1007/s10096-012-1776-6>.
34. Subramanyam B, Sivaramakrishnan G, Dusthacker A, Kumar V. 2013. Phage lysis to control the overgrowth of normal flora in processed sputum samples for the rapid and sensitive detection of *Mycobacterium tuberculosis* by luciferase reporter phage assay. *BMC Infect Dis* 13:44. <http://dx.doi.org/10.1186/1471-2334-13-44>.
35. Kelly P, Matthewman L, Beati L, Raoult D, Mason P, Dreary M, Makombe R. 1992. African tick-bite fever: a new spotted fever group rickettsiosis under an old name. *Lancet* 340:982–983. [http://dx.doi.org/10.1016/0140-6736\(92\)92878-J](http://dx.doi.org/10.1016/0140-6736(92)92878-J).
36. Perry RD, Fetherston JD. 1997. *Yersinia pestis*—etiologic agent of plague. *Clin Microbiol Rev* 10:35–66.
37. Fenollar F, La Scola B, Inokuma H, Dumler JS, Taylor MJ, Raoult D. 2003. Culture and phenotypic characterization of a *Wolbachia pipientis* isolate. *J Clin Microbiol* 41:5434–5441. <http://dx.doi.org/10.1128/JCM.41.12.5434-5441.2003>.
38. Noguchi H, Battistini TS. 1926. Etiology of Oroya fever: I. Cultivation of *Bartonella bacilliformis*. *J Exp Med* 43:851–864.
39. Leake CJ, Varma MG, Pudney M. 1977. Cytopathic effect and plaque formation by arboviruses in a continuous cell line (XTC-2) from the toad *Xenopus laevis*. *J Gen Virol* 35:335–339.
40. Raoult D, La Scola B, Enea M, Fournier PE, Roux V, Fenollar F, Galvao MA, De Lamballerie X. 2001. A flea-associated *Rickettsia* pathogenic for humans. *Emerg Infect Dis* 7:73–81. <http://dx.doi.org/10.3201/eid0701.010112>.
41. Eller C, Crabill MR, Bryant MP. 1971. Anaerobic roll tube media for nonselective enumeration and isolation of bacteria in human feces. *Appl Microbiol* 22:522–529.
42. Nottingham PM, Hungate RE. 1968. Isolation of methanogenic bacteria from feces of man. *J Bacteriol* 96:2178–2179.
43. Fitzgerald C, Nachamkin I. 2007. *Campylobacter* and *Arcobacter*, p 933–946. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), *Manual of clinical microbiology*, 9th ed. ASM Press, Washington, DC.
44. Ghodbane R, Raoult D, Drancourt M. 2014. Dramatic reduction of culture time of *Mycobacterium tuberculosis*. *Sci Rep* 4:4236. <http://dx.doi.org/10.1038/srep04236>.
45. Chapin KC. 2007. Principles of stains and media, p 182–191. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), *Manual of clinical microbiology*, 9th ed. ASM Press, Washington, DC.
46. Marshall BJ, Warren JR. 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* i:1311–1315.
47. Gasquet S, Maurin M, Brouqui P, Lepidi H, Raoult D. 1998. Bacillary angiomatosis in immunocompromised patients. *AIDS* 12:1793–1803. <http://dx.doi.org/10.1097/00002030-199814000-00011>.
48. La Scola B, Raoult D. 1999. Culture of *Bartonella quintana* and *Bartonella henselae* from human samples: a 5-year experience (1993 to 1998). *J Clin Microbiol* 37:1899–1905.
49. Brouqui P, La Scola B, Roux V, Raoult D. 1999. Chronic *Bartonella quintana* bacteremia in homeless patients. *N Engl J Med* 340:184–189. <http://dx.doi.org/10.1056/NEJM199901213400303>.
50. Edelstein PH. 2007. *Legionella*, p 835–849. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), *Manual of clinical microbiology*, 9th ed. ASM Press, Washington, DC.
51. Conville PS, Witebsky FG. 2007. *Nocardia*, *Rhododococcus*, *Gordonia*, *Actinomyces*, *Streptomyces*, and other aerobic Actinomycetes, p 515–542. In Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), *Manual of clinical microbiology*, 9th ed. ASM Press, Washington, DC.
52. Musser JM, Gonzalez R. 2011. Efficacy of an anaerobic swab transport system to maintain aerobic and anaerobic microorganism viability after storage at –80 degrees C. *J Vet Diagn Invest* 23:95–99. <http://dx.doi.org/10.1177/104063871102300115>.
53. Collee JG. 1980. Factors contributing to loss of anaerobic bacteria in transit from the patient to the laboratory. *Infection* 8(Suppl 2):S145–S147. <http://dx.doi.org/10.1007/BF01639876>.
54. Van Horn KG, Audette CD, Tucker KA, Sebeck D. 2008. Comparison of 3 swab transport systems for direct release and recovery of aerobic and anaerobic bacteria. *Diagn Microbiol Infect Dis* 62:471–473. <http://dx.doi.org/10.1016/j.diagmicrobio.2008.08.004>.
55. Van Horn KG, Audette CD, Sebeck D, Tucker KA. 2008. Comparison of the Copan ESwab system with two Amies agar swab transport systems

- for maintenance of microorganism viability. *J Clin Microbiol* 46:1655–1658. <http://dx.doi.org/10.1128/JCM.02047-07>.
56. Waites KB, Talkington DF. 2004. *Mycoplasma pneumoniae* and its role as a human pathogen. *Clin Microbiol Rev* 17:697–728. <http://dx.doi.org/10.1128/CMR.17.4.697-728.2004>.
  57. Nocard E, Roux ER. 1898. Le microbe de la péricapnémie. *Ann Inst Pasteur (Paris)* 12:240–262.
  58. Rodwell AW. 1960. Nutrition and metabolism of *Mycoplasma mycoides* var. *mycoides*. *Ann N Y Acad Sci* 79:499–507.
  59. Rodwell AW, Abbot A. 1961. The function of glycerol, cholesterol and long-chain fatty acids in the nutrition of *Mycoplasma mycoides*. *J Gen Microbiol* 25:201–214.
  60. Hayflick L, Chanock RM. 1965. *Mycoplasma* species of man. *Bacteriol Rev* 29:185–221.
  61. Salaman MH. 1946. Non-specific genital infections; the isolation of organisms of the pleuropneumonia group from the genital tract and their relation to the gonococcus. *Br J Vener Dis* 22:47–55.
  62. Edward DG, Fitzgerald WA. 1951. Cholesterol in the growth of organisms of the pleuropneumonia group. *J Gen Microbiol* 5:576–586.
  63. Smith PF, Lynn RJ. 1958. Lipid requirements for the growth of pleuropneumonia-like organisms. *J Bacteriol* 76:264–269.
  64. Smith PF, Lecce JG, Lynn RJ. 1954. A lipoprotein as a growth factor for certain pleuropneumonia-like organisms. *J Bacteriol* 68:627–633.
  65. Chanock RM, Hayflick L, Barile MF. 1962. Growth on artificial medium of an agent associated with atypical pneumonia and its identification as a PPLO. *Proc Natl Acad Sci U S A* 48:41–49. <http://dx.doi.org/10.1073/pnas.48.1.41>.
  66. Chanock RM, Mufson MA, James WD, Fox HH, Bloom HH, Forsyth B. 1962. Recovery of PPLO of atypical pneumonia on artificial agar medium. *Proc Soc Exp Biol Med* 110:543–547.
  67. Tully JG, Rose DL, Whitcomb RF, Wenzel RP. 1979. Enhanced isolation of *Mycoplasma pneumoniae* from throat washings with a newly-modified culture medium. *J Infect Dis* 139:478–482. <http://dx.doi.org/10.1093/infdis/139.4.478>.
  68. Ollivier B, Caumette P, Garcia JL, Mah RA. 1994. Anaerobic bacteria from hypersaline environments. *Microbiol Rev* 58:27–38.
  69. Stams AJ. 1994. Metabolic interactions between anaerobic bacteria in methanogenic environments. *Antonie Van Leeuwenhoek* 66:271–294. <http://dx.doi.org/10.1007/BF00871644>.
  70. Moore WE, Cato EP, Holdeman LV. 1969. Anaerobic bacteria of the gastrointestinal flora and their occurrence in clinical infections. *J Infect Dis* 119:641–649. <http://dx.doi.org/10.1093/infdis/119.6.641>.
  71. Wilson JR, Limaye AP. 2004. Risk factors for mortality in patients with anaerobic bacteremia. *Eur J Clin Microbiol Infect Dis* 23:310–316. <http://dx.doi.org/10.1007/s10096-004-1111-y>.
  72. Loesche WJ. 1969. Oxygen sensitivity of various anaerobic bacteria. *Appl Microbiol* 18:723–727.
  73. Tally FP, Stewart PR, Sutter VL, Rosenblatt JE. 1975. Oxygen tolerance of fresh clinical anaerobic bacteria. *J Clin Microbiol* 11:161–164.
  74. Biswas S, Rolain JM. 2013. Use of MALDI-TOF mass spectrometry for identification of bacteria that are difficult to culture. *J Microbiol Methods* 92:14–24. <http://dx.doi.org/10.1016/j.mimet.2012.10.014>.
  75. Bryant MP. 1972. Commentary on the Hungate technique for culture of anaerobic bacteria. *Am J Clin Nutr* 25:1324–1328.
  76. Hungate RE. 1969. A roll-tube method for the cultivation of strict anaerobes. *Methods Microbiol* 3B:117–132.
  77. Hensgens CMH, Nienhuis-Kuiper ME, Hansen TA. 1994. Effects of tungstate on the growth of *Desulfovibrio gigas* NCIMB 9332 and other sulfate-reducing bacteria with ethanol as a substrate. *Arch Microbiol* 162:143–147.
  78. Jarrell KF, Kalmokoff ML. 1988. Nutritional requirements of the methanogenic archaeobacteria. *Can J Microbiol* 34:557–576. <http://dx.doi.org/10.1139/m88-095>.
  79. Scherer P, Sahn H. 1981. Effect of trace elements and vitamins on the growth of *Methanosarcina barkeri*. *Acta Biotechnol* 1:57–65. <http://dx.doi.org/10.1002/abio.370010108>.
  80. Schonheit P, Moll J, Thauer RK. 1979. Nickel, cobalt, and molybdenum requirement for growth of *Methanobacterium thermoautotrophicum*. *Arch Microbiol* 123:105–107.
  81. Tanner RS, Wolfe RS. 1988. Nutritional requirements of *Methanococcus mobile*. *Appl Environ Microbiol* 54:625–628.
  82. Hall IC. 1929. A review of the development and application of physical and chemical principles in the cultivation of obligately anaerobic bacteria. *J Bacteriol* 17:255–301.
  83. Dowell VR, Jr. 1974. Collection of clinical specimens and primary isolation of anaerobic bacteria, p 9–20. *In* Balows A (ed), *Anaerobic bacteria: role in diseases*, 1st ed, Charles C Thomas, Springfield, IL.
  84. Ryu E. 1963. The influence of CO(2) supply on colonial formation of leptospire. *Can J Comp Med Vet Sci* 27:261–266.
  85. James-Holmquest AN, Wende RD, Mudd RL, Williams RP. 1973. Comparison of atmospheric conditions for culture of clinical specimens of *Neisseria gonorrhoeae*. *Appl Microbiol* 26:466–469.
  86. Barton LL, Tomei FA. 1995. Characteristics and activities of sulfate-reducing bacteria, p 1–32. *In* Barton LL (ed), *Sulfate-reducing bacteria*. Springer, New York, NY.
  87. La Scola B, Khelafia S, Lagier JC, Raoult D. 2014. Aerobic culture of anaerobic bacteria using antioxidants: a preliminary report. *Eur J Clin Microbiol Infect Dis* 33:1781–1783. <http://dx.doi.org/10.1007/s10096-014-2137-4>.
  88. Martin WJ. 1971. Practical method for isolation of anaerobic bacteria in the clinical laboratory. *Appl Microbiol* 22:1168–1171.
  89. Hanson CW, Martin WJ. 1976. Evaluation of enrichment, storage, and age of blood agar medium in relation to its ability to support growth of anaerobic bacteria. *J Clin Microbiol* 4:394–399.
  90. Plugge CM. 2005. Anoxic media design, preparation, and considerations. *Methods Enzymol* 397:3–16. [http://dx.doi.org/10.1016/S0076-6879\(05\)97001-8](http://dx.doi.org/10.1016/S0076-6879(05)97001-8).
  91. Tchobanoglous G, Burton FL. 1991. *Wastewater engineering: treatment, disposal, and reuse*. McGraw-Hill, New York, NY.
  92. Gibbons RJ, Mc Donald JB. 1960. Hemin and vitamin K compounds as required factors for the cultivation of certain strains of *Bacteroides melanogenicus*. *J Bacteriol* 80:164–170.
  93. Wilkins TD, Chalgren S. 1976. Medium for use in antibiotic susceptibility testing of anaerobic bacteria. *Antimicrob Agents Chemother* 10:926–928. <http://dx.doi.org/10.1128/AAC.10.6.926>.
  94. Hungate RE, Bryant MP, Mah RA. 1964. The rumen bacteria and protozoa. *Annu Rev Microbiol* 18:131–166. <http://dx.doi.org/10.1146/annurev.mi.18.100164.001023>.
  95. Salanitro JP, Fairchild IG, Zgornicki YD. 1974. Isolation, culture characteristics, and identification of anaerobic bacteria from the chicken cecum. *Appl Microbiol* 27:678–687.
  96. Salanitro JP, Blake IG, Muirhead PA. 1977. Isolation and identification of fecal bacteria from adult swine. *Appl Environ Microbiol* 33:79–84.
  97. Miller TL, Wolin MJ, Conway de Macario E, Macario AJ. 1982. Isolation of *Methanobrevibacter smithii* from human feces. *Appl Environ Microbiol* 43:227–232.
  98. Khelafia S, Raoult D, Drancourt M. 2013. A versatile medium for cultivating methanogenic archaea. *PLoS One* 8:e61563. <http://dx.doi.org/10.1371/journal.pone.0061563>.
  99. Speers AM, Cologgi DL, Reguera G. 2009. Anaerobic cell culture. *Curr Protoc Microbiol Appendix 4:Appendix 4F*. <http://dx.doi.org/10.1002/9780471729259.mca04fs12>.
  100. Nottingham PM, Hungate RE. 1969. Methanogenic fermentation of benzoate. *J Bacteriol* 98:1170–1172.
  101. Hungate RE. 1950. The anaerobic mesophilic cellulolytic bacteria. *Bacteriol Rev* 14:1–49.
  102. Vervaeke IJ, Van Nevel CJ. 1972. Comparison of three techniques for the total count of anaerobes from intestinal contents of pigs. *Appl Microbiol* 24:513–515.
  103. Baron EJ. 2011. Approaches to identification of anaerobic bacteria, p 799–802. *In* Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW (ed), *Manual of clinical microbiology*, 10th ed, vol 1. ASM Press, Washington, DC.
  104. Summanen PH, McTeague M, Vaisanen ML, Strong CA, Finegold SM. 1999. Comparison of recovery of anaerobic bacteria using the Anoxomat, anaerobic chamber, and GasPak jar systems. *Anaerobe* 5:5–9. <http://dx.doi.org/10.1006/anae.1999.0184>.
  105. Aranki A, Freter R. 1972. Use of anaerobic glove boxes for the cultivation of strictly anaerobic bacteria. *Am J Clin Nutr* 25:1329–1334.
  106. Leach PA, Bullen JJ, Grant ID. 1971. Anaerobic CO<sub>2</sub> cabinet for the cultivation of strict anaerobes. *Appl Microbiol* 22:824–827.
  107. Magnuson HJ, Eagle H, Fleischman R. 1948. The minimal infectious inoculum of *Spirochaeta pallida* (Nichols strain) and a consideration of its rate of multiplication in vivo. *Am J Syph Gonorrhea Vener Dis* 32:1–18.

108. Hovind-Hougen K, Birch-Andersen A, Henrik-Nielsen R, Orholm M, Pedersen JO, Teglbjaerg PS, Thaysen EH. 1982. Intestinal spirochetosis: morphological characterization and cultivation of the spirochete *Brachyspira aalborgi* gen. nov., sp. nov. *J Clin Microbiol* 16:1127–1136.
109. Hampson DJ, Oxberry SL, La T. 2006. Potential for zoonotic transmission of *Brachyspira pilosicoli*. *Emerg Infect Dis* 12:869–870. <http://dx.doi.org/10.3201/eid1205.051180>.
110. Westerman LJ, Stel HV, Schipper ME, Bakker LJ, Neeffjes-Borst EA, van den Brande JH, Boel EC, Seldenrijk KA, Siersema PD, Bonten MJ, Kusters JG. 2012. Development of a real-time PCR for identification of *Brachyspira* species in human colonic biopsies. *PLoS One* 7:e52281. <http://dx.doi.org/10.1371/journal.pone.0052281>.
111. Kumar GL, Gill GW. 2010. Introduction to special stains. *Connection* 14:16–42.
112. Schwaiger M, Peter O, Cassinotti P. 2001. Routine diagnosis of *Borrelia burgdorferi* (sensu lato) infections using a real-time PCR assay. *Clin Microbiol Infect* 7:461–469. <http://dx.doi.org/10.1046/j.1198-743x.2001.00282.x>.
113. Renesto P, Lorvellec-Guillon K, Drancourt M, Raoult D. 2000. rpoB gene analysis as a novel strategy for identification of spirochetes from the genera *Borrelia*, *Treponema*, and *Leptospira*. *J Clin Microbiol* 38:2200–2203.
114. Paster BJ. 2010. Phylum XV. Spirochaetes phyl. nov., p 471–566. *In* Krieg NR, Parte A, Ludwig W, Whitman W, Hedlund BP, Paster BJ, Staley JT, Ward N, Brown D (ed), *Bergey's manual of systematic bacteriology*, 2nd ed, vol 4. Springer, New York, NY.
115. Zuerner RL. 2011. Genus *Leptospira* Noguchi 1917, 755AL emend. Faine and Stallman 1982, 461, p 546–555. *In* Krieg N, Staley J, Brown D, Hedlund B, Paster B, Ward N, Wolfgang L, Whitman W (ed), *Bergey's manual of systematic bacteriology*, 2nd ed. Springer, New York, NY.
116. Picardeau M. 2013. Diagnosis and epidemiology of leptospirosis. *Med Mal Infect* 43:1–9. <http://dx.doi.org/10.1016/j.medmal.2012.11.005>.
117. Ellinghausen HC, Jr, McCullough WG. 1965. Nutrition of *Leptospira pomona* and growth of 13 other serotypes: fractionation of oleic albumin complex and a medium of bovine albumin and polysorbate 80. *Am J Vet Res* 26:45–51.
118. Arzouni JP, Parola P, La Scola B, Postic D, Brouqui P, Raoult D. 2002. Human infection caused by *Leptospira* fainei. *Emerg Infect Dis* 8:865–868. <http://dx.doi.org/10.3201/eid0808.010445>.
119. Wuthiekanun V, Amornchai P, Paris DH, Langla S, Thaipadunpanit J, Chierakul W, Smythe LD, White NJ, Day NP, Limmathurotsakul D, Peacock SJ. 2013. Rapid isolation and susceptibility testing of *Leptospira* spp. using a new solid medium, LVW agar. *Antimicrob Agents Chemother* 57:297–302. <http://dx.doi.org/10.1128/AAC.01812-12>.
120. Singh S, Kowalczywska M, Edouard S, Eldin C, Perreal C, Weber P, Azza S, Raoult D. 2013. Cell extract-containing medium for culture of intracellular fastidious bacteria. *J Clin Microbiol* 51:2599–2607. <http://dx.doi.org/10.1128/JCM.00719-13>.
121. Smajs D, Zbanikova M, Strouhal M, Cejkova D, Dugan-Rocha S, Pospisilova P, Norris SJ, Albert T, Qin X, Hallsworth-Pepin K, Buhay C, Muzny DM, Chen L, Gibbs RA, Weinstock GM. 2011. Complete genome sequence of *Treponema paraluis-cuniculi*, strain Cuniculi A: the loss of infectivity to humans is associated with genome decay. *PLoS One* 6:e20415. <http://dx.doi.org/10.1371/journal.pone.0020415>.
122. Visser MB, Ellen RP. 2011. New insights into the emerging role of oral spirochaetes in periodontal disease. *Clin Microbiol Infect* 17:502–512. <http://dx.doi.org/10.1111/j.1469-0691.2011.03460.x>.
123. Cutler SJ, Abdissa A, Trape JF. 2009. New concepts for the old challenge of African relapsing fever borreliosis. *Clin Microbiol Infect* 15:400–406. <http://dx.doi.org/10.1111/j.1469-0691.2009.02819.x>.
124. Elbir H, Raoult D, Drancourt M. 2013. Relapsing fever borreliae in Africa. *Am J Trop Med Hyg* 89:288–292. <http://dx.doi.org/10.4269/ajtmh.12-0691>.
125. Stanek G, Reiter M. 2011. The expanding Lyme *Borrelia* complex—clinical significance of genomic species? *Clin Microbiol Infect* 17:487–493. <http://dx.doi.org/10.1111/j.1469-0691.2011.03492.x>.
126. Barbour AG. 1984. Isolation and cultivation of Lyme disease spirochetes. *Yale J Biol Med* 57:521–525.
127. Kelly R. 1971. Cultivation of *Borrelia hermsi*. *Science* 173:443–444. <http://dx.doi.org/10.1126/science.173.3995.443>.
128. Pollack RJ, Telford SR, III, Spielman A. 1993. Standardization of medium for culturing Lyme disease spirochetes. *J Clin Microbiol* 31:1251–1255.
129. Marques AR, Stock F, Gill V. 2000. Evaluation of a new culture medium for *Borrelia burgdorferi*. *J Clin Microbiol* 38:4239–4241.
130. Kurtti TJ, Munderloh UG, Johnson RC, Ahlstrand GG. 1987. Colony formation and morphology in *Borrelia burgdorferi*. *J Clin Microbiol* 25:2054–2058.
131. Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. 1982. Lyme disease—a tick-borne spirochetosis? *Science* 216:1317–1319. <http://dx.doi.org/10.1126/science.7043737>.
132. Cutler SJ, Fekade D, Hussein K, Knox KA, Melka A, Cann K, Emilianus AR, Warrell DA, Wright DJ. 1994. Successful in-vitro cultivation of *Borrelia recurrentis*. *Lancet* 343:242. [http://dx.doi.org/10.1016/S0140-6736\(94\)91032-4](http://dx.doi.org/10.1016/S0140-6736(94)91032-4).
133. Felsenfeld O. 1965. *Borreliae*, human relapsing fever, and parasite-vector-host relationships. *Bacteriol Rev* 29:46–74.
134. Barbour AG, Hayes SF. 1986. Biology of *Borrelia* species. *Microbiol Rev* 50:381–400.
135. Anda P, Sanchez-Yebra W, del Mar Vetulia M, Perez PE, Rodriguez I, Miller NS, Backenson PB, Benach JL. 1996. A new *Borrelia* species isolated from patients with relapsing fever in Spain. *Lancet* 348:162–165. [http://dx.doi.org/10.1016/S0140-6736\(96\)02332-X](http://dx.doi.org/10.1016/S0140-6736(96)02332-X).
136. Hue F, Ghalyanchi LA, Barbour AG. 2013. Chromosome sequence of *Borrelia miyamotoi*, an uncultivable tick-borne agent of human infection. *Genome Announc* 1(5):e00713–13. <http://dx.doi.org/10.1128/genomeA.00713-13>.
137. Cutler SJ, Akintunde CO, Moss J, Fukunaga M, Kurtenbach K, Talbert A, Zhang H, Wright DJ, Warrell DA. 1999. Successful in vitro cultivation of *Borrelia duttonii* and its comparison with *Borrelia recurrentis*. *Int J Syst Bacteriol* 49(Part 4):1793–1799.
138. Schwan TG, Anderson JM, Lopez JE, Fischer RJ, Raffel SJ, McCoy BN, Safronetz D, Sogoba N, Maiga O, Traore SF. 2012. Endemic foci of the tick-borne relapsing fever spirochete *Borrelia crocidurae* in Mali, West Africa, and the potential for human infection. *PLoS Negl Trop Dis* 6:e1924. <http://dx.doi.org/10.1371/journal.pntd.0001924>.
139. Schwan TG, Raffel SJ, Schrumpf ME, Schrumpf ME, Webster LS, Marques AR, Spano R, Rood M, Burns J, Hu R. 2009. Tick-borne relapsing fever and *Borrelia hermsi*, Los Angeles County, California, USA. *Emerg Infect Dis* 15:1026–1031. <http://dx.doi.org/10.3201/eid1507.090223>.
140. Singh S, Eldin C, Kowalczywska M, Raoult D. 2013. Axenic culture of fastidious and intracellular bacteria. *Trends Microbiol* 21:92–99. <http://dx.doi.org/10.1016/j.tim.2012.10.007>.
141. Drancourt M, Gevaudan MJ, Truffot C, Jarlier V. 2003. Growth on blood agar discriminates *Mycobacterium avium* and *Mycobacterium intracellulare*. *Clin Microbiol Infect* 9:1028–1030. <http://dx.doi.org/10.1046/j.1469-0691.2003.00706.x>.
142. Ben Salah I, Drancourt M. 2010. Surviving within the amoebal exocyst: the *Mycobacterium avium* complex paradigm. *BMC Microbiol* 10:99. <http://dx.doi.org/10.1186/1471-2180-10-99>.
143. Truman RW, Singh P, Sharma R, Busso P, Rougemont J, Paniz-Mondolfi A, Kapopoulou A, Brisse S, Scollard DM, Gillis TP, Cole ST. 2011. Probable zoonotic leprosy in the southern United States. *N Engl J Med* 364:1626–1633. <http://dx.doi.org/10.1056/NEJMoa1010536>.
144. Coban AY, Uzun M, Bozdogan B. 2013. Evaluation of agar based medium with sheep sera for drug susceptibility testing of *Mycobacterium tuberculosis* to isoniazid, rifampicin, ethambutol and streptomycin. *J Clin Microbiol* 51:4243–4245. <http://dx.doi.org/10.1128/JCM.01947-13>.
145. Lindeboom JA, Bruijnesteijn van Coppenraet LES, van Soolingen D, Prins JM, Kuijper EJ. 2011. Clinical manifestations, diagnosis, and treatment of *Mycobacterium haemophilum* infections. *Clin Microbiol Rev* 24:701–717. <http://dx.doi.org/10.1128/CMR.00020-11>.
146. Bottger EC, Hirschel B, Coyle MB. 1993. *Mycobacterium genavense* sp. nov. *Int J Syst Bacteriol* 43:841–843. <http://dx.doi.org/10.1099/00207173-43-4-841>.
147. El Khechine A, Couderc C, Flaudrops C, Raoult D, Drancourt M. 2011. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification of mycobacteria in routine clinical practice. *PLoS One* 6:e24720. <http://dx.doi.org/10.1371/journal.pone.0024720>.
148. Adekambi T, Ben Salah S, Khelif M, Raoult D, Drancourt M. 2006. Survival of environmental mycobacteria in *Acanthamoeba* polyphaga. *Appl Environ Microbiol* 72:5974–5981. <http://dx.doi.org/10.1128/AEM.03075-05>.
149. Drancourt M, Adekambi T, Raoult D. 2007. Interactions between *Mycobacterium xenopi*, amoeba and human cells. *J Hosp Infect* 65:138–142. <http://dx.doi.org/10.1016/j.jhin.2006.10.006>.

150. Mba Medie F, Ben Sallah I, Henrissat B, Raoult D, Drancourt M. 2011. Mycobacterium tuberculosis complex mycobacteria as amoeba-resistant organisms. *PLoS One* 6:e20499. <http://dx.doi.org/10.1371/journal.pone.0020499>.
151. Lahiri R, Krahenbuhl JL. 2008. The role of free-living pathogenic amoeba in the transmission of leprosy: a proof of principle. *Lepr Rev* 79:401–409.
152. Gryseels S, Amisshah D, Durnez L, Vandelanooote K, Leirs H, De Jonckheere J, Silva MT, Portaels F, Ablordey A, Eddyani M. 2012. Amoebae as potential environmental hosts for Mycobacterium ulcerans and other mycobacteria, but doubtful actors in Buruli ulcer epidemiology. *PLoS Negl Trop Dis* 6:e1764. <http://dx.doi.org/10.1371/journal.pntd.0001764>.
153. Hartwig NG, Warris A, van de Vos E, van der Zanden AGM, Schulin-Casonato T, van Ingen J, van Hest R. 2011. “Mycobacterium tuberculosis” infection in two immunocompromised children: importance of molecular tools in culture-negative mycobacterial disease diagnosis. *J Clin Microbiol* 49:4409–4411. <http://dx.doi.org/10.1128/JCM.05460-11>.
154. Lagier JC, Armougom F, Million M, Hugon P, Pagnier I, Robert C, Bittar F, Fournous G, Gimenez G, Maraninchi M, Trape JF, Koonin EV, La Scola B, Raoult D. 2012. Microbial culturomics: paradigm shift in the human gut microbiome study. *Clin Microbiol Infect* 18:1185–1193. <http://dx.doi.org/10.1111/1469-0691.12023>.
155. Woese CR, Fox GE. 1977. Phylogenetic structure of the prokaryotic domain: the primary kingdoms. *Proc Natl Acad Sci U S A* 74:5088–5090. <http://dx.doi.org/10.1073/pnas.74.11.5088>.
156. Woese CR, Gupta R. 1981. Are archaeobacteria merely derived ‘prokaryotes’? *Nature* 289:95–96. <http://dx.doi.org/10.1038/289095a0>.
157. Brochier-Armanet C, Boussau B, Gribaldo S, Forterre P. 2008. Mesophilic Crenarchaeota: proposal for a third archaeal phylum, the Thaumarchaeota. *Nat Rev Microbiol* 6:245–252. <http://dx.doi.org/10.1038/nrmicro1852>.
158. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggert CM, Nelson KE. 2006. Metagenomic analysis of the human distal gut microbiome. *Science* 312:1355–1359. <http://dx.doi.org/10.1126/science.1124234>.
159. Borrel G, Harris HM, Parisot N, Gaci N, Tottey W, Mihajlovski A, Deane J, Gribaldo S, Bardot O, Peyretailade E, Peyret P, O’Toole PW, Brugere JF. 2013. Genome sequence of “Candidatus Methanomassiliicoccus intestinalis” Isoire-Mx1, a third Thermoplasmatales-related methanogenic archaeon from human feces. *Genome Announc* 1(4): e00453-13 <http://dx.doi.org/10.1128/genomeA.00453-13>.
160. Hoffmann G, Dollive S, Grunberg S, Chen J, Li H, Wu GD, Lewis JD, Bushmann FD. 2013. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. *PLoS One* 8:e66019. <http://dx.doi.org/10.1371/journal.pone.0066019>.
161. Rieu-Lesme F, Delbes C, Sollelis L. 2005. Recovery of partial 16S rDNA sequences suggests the presence of Crenarchaeota in the human digestive ecosystem. *Curr Microbiol* 51:317–321. <http://dx.doi.org/10.1007/s00284-005-0036-8>.
162. Nam YD, Chang HW, Kim KH, Roh SW, Kim MS, Jung MJ, Lee SW, Kim JY, Yoon JH, Bae JW. 2008. Bacterial, archaeal, and eukaryal diversity in the intestines of Korean people. *J Microbiol* 46:491–501. <http://dx.doi.org/10.1007/s12275-008-0199-7>.
163. Mihajlovski A, Alric M, Brugere JF. 2008. A putative new order of methanogenic Archaea inhabiting the human gut, as revealed by molecular analyses of the mcrA gene. *Res Microbiol* 159:516–521. <http://dx.doi.org/10.1016/j.resmic.2008.06.007>.
164. Scanlan PD, Shanahan F, Marchesi JR. 2008. Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. *BMC Microbiol* 8:79. <http://dx.doi.org/10.1186/1471-2180-8-79>.
165. Probst AJ, Auerbach AK, Moissl-Eichinger C. 2013. Archaea on human skin. *PLoS One* 8:e65388. <http://dx.doi.org/10.1371/journal.pone.0065388>.
166. Caporaso JG, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A, Stombaugh J, Knights D, Gajer P, Ravel J, Fierer N, Gordon JI, Knight R. 2011. Moving pictures of the human microbiome. *Genome Biol* 12: R50. <http://dx.doi.org/10.1186/gb-2011-12-5-r50>.
167. Hulcr J, Latimer AM, Henley JB, Rountree NR, Fierer N, Lucky A, Lowman MD, Dunn RR. 2012. A jungle in there: bacteria in belly buttons are highly diverse, but predictable. *PLoS One* 7:e47712. <http://dx.doi.org/10.1371/journal.pone.0047712>.
168. Dridi B, Raoult D, Drancourt M. 2011. Archaea as emerging organisms in complex human microbiomes. *Anaerobe* 17:56–63. <http://dx.doi.org/10.1016/j.anaerobe.2011.03.001>.
169. Santiago-Rodriguez TM, Narganes-Storde YM, Chanlatte L, Crespo-Torres E, Toranzos GA, Jimenez-Flores R, Hamrick A, Cano RJ. 2013. Microbial communities in pre-Columbian coprolites. *PLoS One* 8:e65191. <http://dx.doi.org/10.1371/journal.pone.0065191>.
170. Khelaifia S, Ramonet PY, Bedotto BM, Drancourt M. 2013. A semi-automated protocol for Archaea DNA extraction from stools. *BMC Res Notes* 6:186. <http://dx.doi.org/10.1186/1756-0500-6-186>.
171. Mihajlovski A, Dore J, Levenez F, Alric M, Brugere JF. 2010. Molecular evaluation of the human gut methanogenic archaeal microbiota reveals an age-associated increase of the diversity. *Environ Microbiol Rep* 2:272–280. <http://dx.doi.org/10.1111/j.1758-2229.2009.00116.x>.
172. Fernandes J, Wang A, Su W, Rozenbloom SR, Taibi A, Comelli EM, Wolever TM. 2013. Age, dietary fiber, breath methane, and fecal short chain fatty acids are interrelated in Archaea-positive humans. *J Nutr* 143:1269–1275. <http://dx.doi.org/10.3945/jn.112.170894>.
173. Dridi B, Henry M, Richet H, Raoult D, Drancourt M. 2012. Age-related prevalence of Methanomassiliicoccus luminyensis in the human gut microbiome. *APMIS* 120:773–777. <http://dx.doi.org/10.1111/j.1600-0463.2012.02899.x>.
174. Borrel G, Harris HM, Tottey W, Mihajlovski A, Parisot N, Peyretailade E, Peyret P, Gribaldo S, O’Toole PW, Brugere JF. 2012. Genome sequence of “Candidatus Methanomethylphilus alvus” Mx1201, a methanogenic archaeon from the human gut belonging to a seventh order of methanogens. *J Bacteriol* 194:6944–6945. <http://dx.doi.org/10.1128/JB.01867-12>.
175. Armougom F, Henry M, Vialettes B, Raccach D, Raoult D. 2009. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and methanogens in anorexic patients. *PLoS One* 4:e7125. <http://dx.doi.org/10.1371/journal.pone.0007125>.
176. Lepp PW, Brinig MM, Ouverney CC, Palm K, Armitage GC, Relman DA. 2004. Methanogenic Archaea and human periodontal disease. *Proc Natl Acad Sci U S A* 101:6176–6181. <http://dx.doi.org/10.1073/pnas.0308766101>.
177. Bringuier A, Khelaifia S, Richet H, Aboudharam G, Drancourt M. 2013. Real-time PCR quantification of Methanobrevibacter oralis in periodontitis. *J Clin Microbiol* 51:993–994. <http://dx.doi.org/10.1128/JCM.02863-12>.
178. Oxley AP, Lanfranconi MP, Wurdemann D, Ott S, Schreiber S, McGenity TJ, Timmis KN, Nogales B. 2010. Halophilic archaea in the human intestinal mucosa. *Environ Microbiol* 12:2398–2410. <http://dx.doi.org/10.1111/j.1462-2920.2010.02212.x>.
179. Dridi B, Fardeau ML, Ollivier B, Raoult D, Drancourt M. 2012. Methanomassiliicoccus luminyensis gen. nov., sp. nov., a methanogenic archaeon isolated from human faeces. *Int J Syst Evol Microbiol* 62:1902–1907. <http://dx.doi.org/10.1099/ijs.0.033712-0>.
180. Gorlas A, Robert C, Gimenez G, Drancourt M, Raoult D. 2012. Complete genome sequence of Methanomassiliicoccus luminyensis, the largest genome of a human-associated Archaea species. *J Bacteriol* 194: 4745. <http://dx.doi.org/10.1128/JB.00956-12>.
181. Borrel G, O’Toole PW, Harris HM, Peyret P, Brugere JF, Gribaldo S. 2013. Phylogenomic data support a seventh order of methylotrophic methanogens and provide insights into the evolution of methanogenesis. *Genome Biol Evol* 5:1769–1780. <http://dx.doi.org/10.1093/gbe/evt128>.
182. Samuel BS, Hansen EE, Manchester JK, Coutinho PM, Henrissat B, Fulton R, Latreille P, Kim K, Wilson RK, Gordon JI. 2007. Genomic and metabolic adaptations of Methanobrevibacter smithii to the human gut. *Proc Natl Acad Sci U S A* 104:10643–10648. <http://dx.doi.org/10.1073/pnas.0704189104>.
183. Miller TL, Wolin MJ. 1985. Methanosphaera stadtmaniae gen. nov., sp. nov.: a species that forms methane by reducing methanol with hydrogen. *Arch Microbiol* 141:116–122.
184. Ferrari A, Brusa T, Rutili A, Canzi E, Biavati B. 1994. Isolation and characterization of Methanobrevibacter oralis sp. nov. *Curr Microbiol* 29:7–12. <http://dx.doi.org/10.1007/BF01570184>.
185. Dridi B, Khelaifia S, Fardeau ML, Ollivier B, Drancourt M. 2012. Tungsten-enhanced growth of Methanosphaera stadtmaniae. *BMC Res Notes* 5:238. <http://dx.doi.org/10.1186/1756-0500-5-238>.
186. Hungate RE, Macy J. 1973. The roll-tube method for cultivation of strict anaerobes. *Bull Ecol Res Commun* 17:123–125.

187. Dridi B, Raoult D, Drancourt M. 2012. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification of Archaea: towards the universal identification of living organisms. *APMIS* 120:85–91. <http://dx.doi.org/10.1111/j.1600-0463.2011.02833.x>.
188. Dridi B, Fardeau ML, Ollivier B, Raoult D, Drancourt M. 2011. The antimicrobial resistance pattern of cultured human methanogens reflects the unique phylogenetic position of archaea. *J Antimicrob Chemother* 66:2038–2044. <http://dx.doi.org/10.1093/jac/dkr251>.
189. Khelaifia S, Brunel JM, Raoult D, Drancourt M. 2013. Hydrophobicity of imidazole derivatives correlates with improved activity against human methanogenic archaea. *Int J Antimicrob Agents* 41:544–547. <http://dx.doi.org/10.1016/j.ijantimicag.2013.02.013>.
190. Fricke WF, Seedorf H, Henne A, Krueger M, Liesegang H, Hedderich R, Gottschalk G, Thauer RK. 2006. The genome sequence of *Methanospirillum hutchinsonii* reveals why this human intestinal archaeon is restricted to methanol and H<sub>2</sub> for methane formation and ATP synthesis. *J Bacteriol* 188:642–658. <http://dx.doi.org/10.1128/JB.188.2.642-658.2006>.
191. Matarazzo F, Ribeiro AC, Feres M, Faveri M, Mayer MP. 2011. Diversity and quantitative analysis of Archaea in aggressive periodontitis and periodontally healthy subjects. *J Clin Periodontol* 38:621–627. <http://dx.doi.org/10.1111/j.1600-051X.2011.01734.x>.
192. Horz HP, Seyfarth I, Conrads G. 2012. McrA and 16S rRNA gene analysis suggests a novel lineage of Archaea phylogenetically affiliated with Thermoplasmatales in human subgingival plaque. *Anaerobe* 18:373–377. <http://dx.doi.org/10.1016/j.anaerobe.2012.04.006>.
193. Rinke C, Schwientek P, Szyba A, Ivanova NN, Anderson JJ, Cheng JF, Darling A, Malfatti S, Swan BK, Gies EA, Dodsworth JA, Hedlund BP, Tsiamis G, Sievert SM, Liu WT, Eisen JA, Hallam SJ, Kyrpides NC, Stepanauskas R, Rubin EM, Hugenholtz P, Woyke T. 2013. Insights into the phylogeny and coding potential of microbial dark matter. *Nature* 499:431–437. <http://dx.doi.org/10.1038/nature12352>.
194. Fenollar F, Puechal X, Raoult D. 2007. Whipple's disease. *N Engl J Med* 356:55–66. <http://dx.doi.org/10.1056/NEJMra062477>.
195. Parola P, Paddock CD, Socolovschi C, Labruna MB, Mediannikov O, Kernif T, Abdad MY, Stenos J, Bitam I, Fournier PE, Raoult D. 2013. Update on tick-borne rickettsioses around the world: a geographic approach. *Clin Microbiol Rev* 26:657–702. <http://dx.doi.org/10.1128/CMR.00032-13>.
196. Maurin M, Raoult D. 1999. Q fever. *Clin Microbiol Rev* 12:518–553.
197. Gouriet F, Fenollar F, Patrice JY, Drancourt M, Raoult D. 2005. Use of shell-vial cell culture assay for isolation of bacteria from clinical specimens: 13 years of experience. *J Clin Microbiol* 43:4993–5002. <http://dx.doi.org/10.1128/JCM.43.10.4993-5002.2005>.
198. Omsland A, Hackstadt T, Heinzen RA. 2013. Bringing culture to the uncultured: *Coxiella burnetii* and lessons for obligate intracellular bacterial pathogens. *PLoS Pathog* 9:e1003540. <http://dx.doi.org/10.1371/journal.ppat.1003540>.
199. Goodpasture EW, Woodruff AM, Buddingh GJ. 1931. The cultivation of vaccine and other viruses in the chorioallantoic membrane of chick embryos. *Science* 74:371–372. <http://dx.doi.org/10.1126/science.74.1919.371>.
200. Woodruff AM, Goodpasture EW. 1931. The susceptibility of the chorioallantoic membrane of chick embryos to infection with the fowl-pox virus. *Am J Pathol* 7:209–222.
201. Cox HR. 1938. Use of yolk sac of developing chick embryo as medium for growing rickettsiae of Rocky Mountain spotted fever and typhus groups. *Public Health Rep* 53:2241. <http://dx.doi.org/10.2307/4582741>.
202. Ormsbee RA. 1952. The growth of *Coxiella burnetii* in embryonated eggs. *J Bacteriol* 63:73–86.
203. Anacker RL, Fukushi K, Pickens EG, Lackman DB. 1964. Electron microscopic observations of the development of *Coxiella burnetii* in the chick yolk sac. *J Bacteriol* 88:1130–1138.
204. Raoult D, Roussellier P, Galicher V, Perez R, Tamalet J. 1986. In vitro susceptibility of *Rickettsia conorii* to ciprofloxacin as determined by suppressing lethality in chicken embryos and by plaque assay. *Antimicrob Agents Chemother* 29:424–425. <http://dx.doi.org/10.1128/AAC.29.3.424>.
205. Raoult D, Yeaman MR, Baca OG. 1989. Susceptibility of *Coxiella burnetii* to pefloxacin and ofloxacin in ovo and in persistently infected L929 cells. *Antimicrob Agents Chemother* 33:621–623. <http://dx.doi.org/10.1128/AAC.33.5.621>.
206. Couret M. 1911. The behavior of *Bacillus leprae* in cold-blooded animals. *J Exp Med* 13:576–589. <http://dx.doi.org/10.1084/jem.13.5.576>.
207. Shepard CC. 1962. Multiplication of *Mycobacterium leprae* in the foot-pad of the mouse. *Int J Lepr* 30:291–306.
208. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. 2006. The continuing challenges of leprosy. *Clin Microbiol Rev* 19:338–381. <http://dx.doi.org/10.1128/CMR.19.2.338-381.2006>.
209. Kirchheimer WF, Storrs EE. 1971. Attempts to establish the armadillo (*Dasypus novemcinctus* Linn.) as a model for the study of leprosy. I. Report of lepromatoid leprosy in an experimentally infected armadillo. *Int J Lepr Other Mycobact Dis* 39:693–702.
210. Kirchheimer WF, Storrs EE, Binford CH. 1972. Attempts to establish the armadillo (*Dasypus novemcinctus* Linn.) as a model for the study of leprosy. II. Histopathologic and bacteriologic post-mortem findings in lepromatoid leprosy in the armadillo. *Int J Lepr Other Mycobact Dis* 40:229–242.
211. Sharma R, Lahiri R, Scollard DM, Pena M, Williams DL, Adams LB, Figarola J, Truman RW. 2013. The armadillo: a model for the neuropathy of leprosy and potentially other neurodegenerative diseases. *Dis Model Mech* 6:19–24. <http://dx.doi.org/10.1242/dmm.010215>.
212. La Scola B, Raoult D. 1997. Laboratory diagnosis of rickettsioses: current approaches to diagnosis of old and new rickettsial diseases. *J Clin Microbiol* 35:2715–2727.
213. Radulovic S, Higgins JA, Jaworski DC, Dasch GA, Azad AF. 1995. Isolation, cultivation, and partial characterization of the ELB agent associated with cat fleas. *Infect Immun* 63:4826–4829.
214. Kawahara M, Rikihisa Y, Isogai E, Takahashi M, Misumi H, Suto C, Shibata S, Zhang C, Tsuji M. 2004. Ultrastructure and phylogenetic analysis of *Candidatus Neoehrlichia mikurensis* in the family Anaplasmataceae, isolated from wild rats and found in *Ixodes ovatus* ticks. *Int J Syst Evol Microbiol* 54:1837–1843. <http://dx.doi.org/10.1099/ijs.0.63260-0>.
215. Ridoux O, Foucault C, Drancourt M. 1998. Purification of *Encephalitozoon* cultures contaminated by mycoplasmas by murine intraperitoneal inoculation. *J Clin Microbiol* 36:2380–2382.
216. Eremeeva ME, Balayeva NM, Raoult D. 1994. Purification of rickettsial cultures contaminated by mycoplasmas. *Acta Virol* 38:231–233.
217. Moliner C, Fournier PE, Raoult D. 2010. Genome analysis of microorganisms living in amoebae reveals a melting pot of evolution. *FEMS Microbiol Rev* 34:281–294. <http://dx.doi.org/10.1111/j.1574-6976.2009.00209.x>.
218. Rowbotham TJ. 1980. Preliminary report on the pathogenicity of *Legionella pneumophila* for freshwater and soil amoebae. *J Clin Pathol* 33:1179–1183.
219. Rowbotham TJ. 1983. Isolation of *Legionella pneumophila* from clinical specimens via amoebae, and the interaction of those and other isolates with amoebae. *J Clin Pathol* 36:978–986.
220. Greub G, Raoult D. 2004. Microorganisms resistant to free-living amoebae. *Clin Microbiol Rev* 17:413–433. <http://dx.doi.org/10.1128/CMR.17.2.413-433.2004>.
221. Berk SG, Faulkner G, Garduno E, Joy MC, Ortiz-Jimenez MA, Garduno RA. 2008. Packaging of live *Legionella pneumophila* into pellets expelled by *Tetrahymena* spp. does not require bacterial replication and depends on a Dot/Icm-mediated survival mechanism. *Appl Environ Microbiol* 74:2187–2199. <http://dx.doi.org/10.1128/AEM.01214-07>.
222. Faulkner G, Berk SG, Garduno E, Ortiz-Jimenez MA, Garduno RA. 2008. Passage through *Tetrahymena* tropicalis triggers a rapid morphological differentiation in *Legionella pneumophila*. *J Bacteriol* 190:7728–7738. <http://dx.doi.org/10.1128/JB.00751-08>.
223. Thomas V, Herrera-Rimann K, Blanc DS, Greub G. 2006. Biodiversity of amoebae and amoeba-resisting bacteria in a hospital water network. *Appl Environ Microbiol* 72:2428–2438. <http://dx.doi.org/10.1128/AEM.72.4.2428-2438.2006>.
224. Pagnier I, Merchat M, Raoult D, La Scola B. 2009. Emerging *Mycobacterium* spp. in cooling towers. *Emerg Infect Dis* 15:121–122. <http://dx.doi.org/10.3201/eid1501.071356>.
225. Birtles RJ, Rowbotham TJ, Storey C, Marrie TJ, Raoult D. 1997. Chlamydia-like obligate parasite of free-living amoebae. *Lancet* 349:925–926. [http://dx.doi.org/10.1016/S0140-6736\(05\)62701-8](http://dx.doi.org/10.1016/S0140-6736(05)62701-8).
226. La Scola B, Boyadjiev I, Greub G, Khamis A, Martin C, Raoult D. 2003. Amoeba-resisting bacteria and ventilator-associated pneumonia. *Emerg Infect Dis* 9:815–821.
227. La Scola B, Desnues C, Pagnier I, Robert C, Barrassi L, Fournous G, Merchat M, Suzan-Monti M, Forterre P, Koonin E, Raoult D. 2008. The virophage as a unique parasite of the giant mimivirus. *Nature* 455:100–104. <http://dx.doi.org/10.1038/nature07218>.

228. Boyer M, Yutin N, Pagnier I, Barrassi L, Fournous G, Espinosa L, Robert C, Azza S, Sun S, Rossmann MG, Suzan-Monti M, La Scola B, Koonin EV, Raoult D. 2009. Giant marseillevirus highlights the role of amoebae as a melting pot in emergence of chimeric microorganisms. *Proc Natl Acad Sci U S A* 106:21848–21853. <http://dx.doi.org/10.1073/pnas.0911354106>.
229. Philippe N, Legendre M, Doutre G, Coute Y, Poirot O, Lescot M, Arslan D, Seltzer V, Bertaux L, Bruley C, Garin J, Claverie JM, Abergel C. 2013. Pandoraviruses: amoeba viruses with genomes up to 2.5 Mb reaching that of parasitic eukaryotes. *Science* 341:281–286. <http://dx.doi.org/10.1126/science.1239181>.
230. Pukatzki S, Kessin RH, Mekalanos JJ. 2002. The human pathogen *Pseudomonas aeruginosa* utilizes conserved virulence pathways to infect the social amoeba *Dictyostelium discoideum*. *Proc Natl Acad Sci U S A* 99:3159–3164. <http://dx.doi.org/10.1073/pnas.052704399>.
231. Fenner L, Richet H, Raoult D, Papazian L, Martin C, La Scola B. 2006. Are clinical isolates of *Pseudomonas aeruginosa* more virulent than hospital environmental isolates in amoeba co-culture test? *Crit Care Med* 34:823–828. <http://dx.doi.org/10.1097/01.CCM.0000201878.51343.F1>.
232. Steinert M, Heuner K. 2005. *Dictyostelium* as host model for pathogenesis. *Cell Microbiol* 7:307–314. <http://dx.doi.org/10.1111/j.1462-5822.2005.00493.x>.
233. Fuchs BB, Mylonakis E. 2006. Using non-mammalian hosts to study fungal virulence and host defense. *Curr Opin Microbiol* 9:346–351. <http://dx.doi.org/10.1016/j.mib.2006.06.004>.
234. Jacquier N, Aeby S, Lienard J, Greub G. 2013. Discovery of new intracellular pathogens by amoebal coculture and amoebal enrichment approaches. *J Vis Exp* 2013:e51055. <http://dx.doi.org/10.3791/51055>.
235. Pagnier I, Raoult D, La Scola B. 2008. Isolation and identification of amoeba-resisting bacteria from water in human environment by using an *Acanthamoeba polyphaga* co-culture procedure. *Environ Microbiol* 10:1135–1144. <http://dx.doi.org/10.1111/j.1462-2920.2007.01530.x>.
236. Horn M, Wagner M. 2004. Bacterial endosymbionts of free-living amoebae. *J Eukaryot Microbiol* 51:509–514. <http://dx.doi.org/10.1111/j.1550-7408.2004.tb00278.x>.
237. Horn M, Wagner M, Muller KD, Schmid EN, Fritsche TR, Schleifer KH, Michel R. 2000. *Neochlamydia hartmannellae* gen. nov., sp. nov. (Parachlamydiaceae), an endoparasite of the amoeba *Hartmannella vermiformis*. *Microbiology* 146(Part 5):1231–1239.
238. Saisongkroh W, Robert C, La Scola B, Raoult D, Rolain JM. 2010. Evidence of transfer by conjugation of type IV secretion system genes between *Bartonella* species and *Rhizobium radiobacter* in amoeba. *PLoS One* 5:e12666. <http://dx.doi.org/10.1371/journal.pone.0012666>.
239. Greub G, La Scola B, Raoult D. 2004. Amoebae-resisting bacteria isolated from human nasal swabs by amoebal coculture. *Emerg Infect Dis* 10:470–477. <http://dx.doi.org/10.3201/eid1003.020792>.
240. Corsaro D, Muller KD, Wingender J, Michel R. 2013. “*Candidatus Mesochlamydia elodeae*” (Chlamydiae: Parachlamydiaceae), a novel chlamydia parasite of free-living amoebae. *Parasitol Res* 112:829–838. <http://dx.doi.org/10.1007/s00436-012-3213-2>.
241. Ogata H, La Scola B, Audic S, Renesto P, Blanc G, Robert C, Fournier PE, Claverie JM, Raoult D. 2006. Genome sequence of *Rickettsia bellii* illuminates the role of amoebae in gene exchanges between intracellular pathogens. *PLoS Genet* 2:e76. <http://dx.doi.org/10.1371/journal.pgen.0020076>.
242. Thomas V, Loret JF, Jousset M, Greub G. 2008. Biodiversity of amoebae and amoebae-resisting bacteria in a drinking water treatment plant. *Environ Microbiol* 10:2728–2745. <http://dx.doi.org/10.1111/j.1462-2920.2008.01693.x>.
243. Steinert M. 2011. Pathogen-host interactions in *Dictyostelium*, *Legionella*, *Mycobacterium* and other pathogens. *Semin Cell Dev Biol* 22:70–76. <http://dx.doi.org/10.1016/j.semcdb.2010.11.003>.
244. Corsaro D, Muller KD, Michel R. 2013. Molecular characterization and ultrastructure of a new amoeba endoparasite belonging to the *Stenotrophomonas maltophilia* complex. *Exp Parasitol* 133:383–390. <http://dx.doi.org/10.1016/j.exppara.2012.12.016>.
245. Rahman M, Abd H, Romling U, Sandstrom G, Mollby R. 2008. *Aeromonas-Acanthamoeba* interaction and early shift to a viable but nonculturable state of *Aeromonas* by *Acanthamoeba*. *J Appl Microbiol* 104:1449–1457. <http://dx.doi.org/10.1111/j.1365-2672.2007.03687.x>.
246. Yousuf FA, Siddiqui R, Khan NA. 2013. *Acanthamoeba castellanii* of the T4 genotype is a potential environmental host for *Enterobacter aerogenes* and *Aeromonas hydrophila*. *Parasit Vectors* 6:169. <http://dx.doi.org/10.1186/1756-3305-6-169>.
247. Merhej V, Adekambi T, Pagnier I, Raoult D, Drancourt M. 2008. *Yersinia massiliensis* sp. nov., isolated from fresh water. *Int J Syst Evol Microbiol* 58:779–784. <http://dx.doi.org/10.1099/ijs.0.65219-0>.
248. Matin A, Jung SY. 2011. Interaction of *Escherichia coli* K1 and K5 with *Acanthamoeba castellanii* trophozoites and cysts. *Korean J Parasitol* 49:349–356. <http://dx.doi.org/10.3347/kjp.2011.49.4.349>.
249. Tamang MD, Kim S, Kim SM, Kong HH, Kim J. 2011. Interaction of *Acinetobacter baumannii* 19606 and 1656-2 with *Acanthamoeba castellanii*. *J Microbiol* 49:841–846. <http://dx.doi.org/10.1007/s12275-011-1063-8>.
250. Adeleke AA, Fields BS, Benson RF, Daneshvar MI, Pruckler JM, Ratcliff RM, Harrison TG, Weyant RS, Birtles RJ, Raoult D, Halablab MA. 2001. *Legionella drozanskii* sp. nov., *Legionella rowbothamii* sp. nov and *Legionella fallonii* sp nov: three unusual new *Legionella* species. *Int J Syst Evol Microbiol* 51:1151–1160. <http://dx.doi.org/10.1099/00207713-51-3-1151>.
251. La Scola B, Birtles RJ, Greub G, Harrison TJ, Ratcliff RM, Raoult D. 2004. *Legionella drancourtii* sp. nov., a strictly intracellular amoebal pathogen. *Int J Syst Evol Microbiol* 54:699–703. <http://dx.doi.org/10.1099/ijs.0.02455-0>.
252. Corsaro D, Pages GS, Catalan V, Loret JF, Greub G. 2010. Biodiversity of amoebae and amoeba-associated bacteria in water treatment plants. *Int J Hyg Environ Health* 213:158–166. <http://dx.doi.org/10.1016/j.ijheh.2010.03.002>.
253. Park M, Yun ST, Kim MS, Chun J, Ahn TI. 2004. Phylogenetic characterization of *Legionella*-like endosymbiotic X-bacteria in *Amoeba proteus*: a proposal for ‘*Candidatus Legionella jeonii*’ sp. nov. *Environ Microbiol* 6:1252–1263. <http://dx.doi.org/10.1111/j.1462-2920.2004.00659.x>.
254. La Scola B, Raoult D. 2001. Survival of *Coxiella burnetii* within free-living amoeba *Acanthamoeba castellanii*. *Clin Microbiol Infect* 7:75–79. <http://dx.doi.org/10.1046/j.1469-0691.2001.00193.x>.
255. El-Etr SH, Margolis JJ, Monack D, Robison RA, Cohen M, Moore E, Rasley A. 2009. *Francisella tularensis* type A strains cause the rapid encystment of *Acanthamoeba castellanii* and survive in amoebal cysts for three weeks postinfection. *Appl Environ Microbiol* 75:7488–7500. <http://dx.doi.org/10.1128/AEM.01829-09>.
256. Axelsson-Olsson D, Waldenstrom J, Broman T, Olsen B, Holmberg M. 2005. Protozoan *Acanthamoeba polyphaga* as a potential reservoir for *Campylobacter jejuni*. *Appl Environ Microbiol* 71:987–992. <http://dx.doi.org/10.1128/AEM.71.2.987-992.2005>.
257. Olofsson J, Axelsson-Olsson D, Brudin L, Olsen B, Ellstrom P. 2013. *Campylobacter jejuni* actively invades the amoeba *Acanthamoeba polyphaga* and survives within non digestive vacuoles. *PLoS One* 8:e78873. <http://dx.doi.org/10.1371/journal.pone.0078873>.
258. Lebbadi M, Valdivia E, Galvez A, Martinez-Bueno M, Maqueda M. 1995. Cocultivation of the amoeba *Naegleria fowleri* and the amoebicid-producing strain *Bacillus licheniformis* M-4. *Appl Environ Microbiol* 61:1649–1652.
259. Beeton ML, Atkinson DJ, Waterfield NR. 2013. An amoeba phagocytosis model reveals a novel developmental switch in the insect pathogen *Bacillus thuringiensis*. *J Insect Physiol* 59:223–231. <http://dx.doi.org/10.1016/j.jinphys.2012.06.011>.
260. Huws SA, Morley RJ, Jones MV, Brown MR, Smith AW. 2008. Interactions of some common pathogenic bacteria with *Acanthamoeba polyphaga*. *FEMS Microbiol Lett* 282:258–265. <http://dx.doi.org/10.1111/j.1574-6968.2008.01123.x>.
261. Evstigneeva A, Raoult D, Karpachevskiy L, La Scola B. 2009. Amoeba co-culture of soil specimens recovered 33 different bacteria, including four new species and *Streptococcus pneumoniae*. *Microbiology* 155:657–664. <http://dx.doi.org/10.1099/mic.0.022970-0>.
262. Bonifait L, Charette SJ, Filion G, Gottschalk M, Grenier D. 2011. Amoeba host model for evaluation of *Streptococcus suis* virulence. *Appl Environ Microbiol* 77:6271–6273. <http://dx.doi.org/10.1128/AEM.00659-11>.
263. Wagner Y, Noack B, Hoffmann T, Jacobs E, Christian LP. 2006. Periodontopathogenic bacteria multiply in the environmental amoeba *Acanthamoeba castellanii*. *Int J Hyg Environ Health* 209:535–539. <http://dx.doi.org/10.1016/j.ijheh.2006.05.006>.
264. Horn M, Harzenetter MD, Linner T, Schmid EN, Muller KD, Michel R, Wagner M. 2001. Members of the *Cytophaga-Flavobacterium*-



- Bacteroides phylum as intracellular bacteria of acanthamoebae: proposal of 'Candidatus Amoebophilus asiaticus'. *Environ Microbiol* 3:440–449. <http://dx.doi.org/10.1046/j.1462-2920.2001.00210.x>.
265. Yu HS, Jeong HJ, Hong YC, Seol SY, Chung DI, Kong HH. 2007. Natural occurrence of Mycobacterium as an endosymbiont of Acanthamoeba isolated from a contact lens storage case. *Korean J Parasitol* 45:11–18. <http://dx.doi.org/10.3347/kjp.2007.45.1.11>.
  266. Cirillo JD, Falkow S, Tompkins LS, Bermudez LE. 1997. Interaction of Mycobacterium avium with environmental amoebae enhances virulence. *Infect Immun* 65:3759–3767.
  267. Steinert M, Birkness K, White E, Fields B, Quinn F. 1998. Mycobacterium avium bacilli grow saprozoically in coculture with Acanthamoeba polyphaga and survive within cyst walls. *Appl Environ Microbiol* 64:2256–2261.
  268. Pozos TC, Ramakrishnan L. 2004. New models for the study of Mycobacterium-host interactions. *Curr Opin Immunol* 16:499–505. <http://dx.doi.org/10.1016/j.coi.2004.05.011>.
  269. Lamrabet O, Mba Medie F, Drancourt M. 2012. Acanthamoeba polyphaga-enhanced growth of Mycobacterium smegmatis. *PLoS One* 7:e29833. <http://dx.doi.org/10.1371/journal.pone.0029833>.
  270. Salah IB, Ghigo E, Drancourt M. 2009. Free-living amoebae, a training field for macrophage resistance of mycobacteria. *Clin Microbiol Infect* 15:894–905. <http://dx.doi.org/10.1111/j.1469-0691.2009.03011.x>.
  271. Kennedy GM, Morisaki JH, Champion PA. 2012. Conserved mechanisms of Mycobacterium marinum pathogenesis within the environmental amoeba Acanthamoeba castellanii. *Appl Environ Microbiol* 78:2049–2052. <http://dx.doi.org/10.1128/AEM.06965-11>.
  272. Lamrabet O, Merhej V, Pontarotti P, Raoult D, Drancourt M. 2012. The genealogic tree of mycobacteria reveals a long-standing sympatric life into free-living protozoa. *PLoS One* 7:e34754. <http://dx.doi.org/10.1371/journal.pone.0034754>.
  273. Mba Mdie F, Ben Sallah I, Drancourt M, Henrissat B. 2010. Paradoxical conservation of a set of three cellulose-targeting genes in Mycobacterium tuberculosis complex organisms. *Microbiology* 156:1468–1475. <http://dx.doi.org/10.1099/mic.0.037812-0>.
  274. Mba Mdie F, Davies GJ, Drancourt M, Henrissat B. 2012. Genome analyses highlight the different biological roles of cellulases. *Nat Rev Microbiol* 10:227–234. <http://dx.doi.org/10.1038/nrmicro2729>.
  275. Pearce MM, Cianciotto NP. 2009. Legionella pneumophila secretes an endoglucanase that belongs to the family-5 of glycosyl hydrolases and is dependent upon type II secretion. *FEMS Microbiol Lett* 300:256–264. <http://dx.doi.org/10.1111/j.1574-6968.2009.01801.x>.
  276. Essig A, Heinemann M, Simnacher U, Marre R. 1997. Infection of Acanthamoeba castellanii by Chlamydia pneumoniae. *Appl Environ Microbiol* 63:1396–1399.
  277. Wirz M, Polkinghorne A, Dumrese C, Ziegler U, Greub G, Pospischil A, Vaughan L. 2008. Predator or prey? Chlamydia abortus infections of a free-living amoeba, Acanthamoeba castellanii 9GU. *Microbes Infect* 10:591–597. <http://dx.doi.org/10.1016/j.micinf.2008.01.006>.
  278. Amann R, Springer N, Schonhuber W, Ludwig W, Schmid EN, Muller KD, Michel R. 1997. Obligate intracellular bacterial parasites of acanthamoebae related to Chlamydia spp. *Appl Environ Microbiol* 63:115–121.
  279. Collingro A, Toenshoff ER, Taylor MW, Fritsche TR, Wagner M, Horn M. 2005. 'Candidatus Protochlamydia amoebophila', an endosymbiont of Acanthamoeba spp. *Int J Syst Evol Microbiol* 55:1863–1866. <http://dx.doi.org/10.1099/ijs.0.63572-0>.
  280. Thomas V, Casson N, Greub G. 2006. Criblamydia sequanensis, a new intracellular Chlamydiales isolated from Seine river water using amoebal co-culture. *Environ Microbiol* 8:2125–2135. <http://dx.doi.org/10.1111/j.1462-2920.2006.01094.x>.
  281. Casson N, Michel R, Muller KD, Aubert JD, Greub G. 2008. Protochlamydia naegleriophila as etiologic agent of pneumonia. *Emerg Infect Dis* 14:168–172. <http://dx.doi.org/10.3201/eid1401.070980>.
  282. Corsaro D, Michel R, Walochnik J, Muller KD, Greub G. 2010. Saccamoeba lacustris, sp. nov. (Amoebozoa: Lobosea: Hartmannellidae), a new lobose amoeba, parasitized by the novel chlamydia 'Candidatus Metachlamydia lacustris' (Chlamydiae: Parachlamydiaceae). *Eur J Protistol* 46:86–95. <http://dx.doi.org/10.1016/j.ejop.2009.11.002>.
  283. Lienard J, Croxatto A, Prod'homme G, Greub G. 2011. Estrella lausannensis, a new star in the Chlamydiales order. *Microbes Infect* 13:1232–1241. <http://dx.doi.org/10.1016/j.micinf.2011.07.003>.
  284. Everett KD, Bush RM, Andersen AA. 1999. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms. *Int J Syst Bacteriol* 49(Part 2):415–440.
  285. Kahane S, Dvoskin B, Mathias M, Friedman MG. 2001. Infection of Acanthamoeba polyphaga with Simkania negevensis and S. negevensis survival within amoebal cysts. *Appl Environ Microbiol* 67:4789–4795. <http://dx.doi.org/10.1128/AEM.67.10.4789-4795.2001>.
  286. Rurangirwa FR, Dilbeck PM, Crawford TB, McGuire TC, McElwain TF. 1999. Analysis of the 16S rRNA gene of micro-organism WSU 86-1044 from an aborted bovine foetus reveals that it is a member of the order Chlamydiales: proposal of Waddliaceae fam. nov., Waddlia chondrophila gen. nov, sp nov. *Int J Syst Bacteriol* 49(Part 2):577–581.
  287. Hugenholtz P, Goebel BM, Pace NR. 1998. Impact of culture-independent studies on the emerging phylogenetic view of bacterial diversity. *J Bacteriol* 180:4765–4774.
  288. Stingl U, Radek R, Yang H, Brune A. 2005. 'Endomicrobia': cytoplasmic symbionts of termite gut protozoa form a separate phylum of prokaryotes. *Appl Environ Microbiol* 71:1473–1479. <http://dx.doi.org/10.1128/AEM.71.3.1473-1479.2005>.
  289. Ikeda-Ohtsubo W, Desai M, Stingl U, Brune A. 2007. Phylogenetic diversity of 'Endomicrobia' and their specific affiliation with termite gut flagellates. *Microbiology* 153:3458–3465. <http://dx.doi.org/10.1099/mic.0.2007/009217-0>.
  290. McLean JS, Lombardo MJ, Badger JH, Edlund A, Novotny M, Yee-Greenbaum J, Vyahhi N, Hall AP, Yang Y, Dupont CL, Ziegler MG, Chitsaz H, Allen AE, Yooshep S, Tesler G, Pevzner PA, Friedman RM, Neelson KH, Venter JC, Lasken RS. 2013. Candidate phylum TM6 genome recovered from a hospital sink biofilm provides genomic insights into this uncultivated phylum. *Proc Natl Acad Sci U S A* 110:E2390–E2399. <http://dx.doi.org/10.1073/pnas.1219809110>.
  291. La Scola B, Mezi L, Weiller PJ, Raoult D. 2001. Isolation of Legionella anisa using an amoebic coculture procedure. *J Clin Microbiol* 39:365–366. <http://dx.doi.org/10.1128/JCM.39.1.365-366.2001>.
  292. Colson P, Fancello L, Gimenez G, Armougom F, Desnues C, Fournous G, Yoosuf N, Million M, La Scola B, Raoult D. 2013. Evidence of the megavirome in humans. *J Clin Virol* 57:191–200. <http://dx.doi.org/10.1016/j.jcv.2013.03.018>.
  293. Saadi H, Pagnier I, Colson P, Cherif JK, Beji M, Boughalmi M, Azza S, Armstrong N, Robert C, Fournous G, La Scola B, Raoult D. 2013. First isolation of mimivirus in a patient with pneumonia. *Clin Infect Dis* 57:e127–e134. <http://dx.doi.org/10.1093/cid/cit354>.
  294. Saadi H, Reteno DG, Colson P, Aherfi S, Minodier P, Pagnier I, Raoult D, La Scola B. 2013. Shan virus: a new mimivirus isolated from the stool of a Tunisian patient with pneumonia. *Intervirology* 56:424–429. <http://dx.doi.org/10.1159/000354564>.
  295. Goy G, Greub G. 2009. Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. *Antimicrob Agents Chemother* 53:2663–2666. <http://dx.doi.org/10.1128/AAC.00046-09>.
  296. Goy G, Croxatto A, Greub G. 2008. Waddlia chondrophila enters and multiplies within human macrophages. *Microbes Infect* 10:556–562. <http://dx.doi.org/10.1016/j.micinf.2008.02.003>.
  297. Boughalmi M, Saadi H, Pagnier I, Colson P, Fournous G, Raoult D, La Scola B. 2013. High-throughput isolation of giant viruses of the Mimiviridae and Marselleviridae families in the Tunisian environment. *Environ Microbiol* 15:2000–2007. <http://dx.doi.org/10.1111/1462-2920.12068>.
  298. Raoult D, Rousellier P, Vestris G, Tamalet J. 1987. In vitro antibiotic susceptibility of Rickettsia rickettsii and Rickettsia conorii: plaque assay and microplaque colorimetric assay. *J Infect Dis* 155:1059–1062. <http://dx.doi.org/10.1093/infdis/155.5.1059>.
  299. Rolain JM, Maurin M, Vestris G, Raoult D. 1998. In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials. *Antimicrob Agents Chemother* 42:1537–1541.
  300. Baca OG, Akporiaye ET, Aragon AS, Martinez IL, Robles MV, Warner NL. 1981. Fate of phase I and phase II Coxiella burnetii in several macrophage-like tumor cell lines. *Infect Immun* 33:258–266.
  301. Baca OG, Scott TO, Akporiaye ET, DeBlasie R, Crissman HA. 1985. Cell cycle distribution patterns and generation times of L929 fibroblast cells persistently infected with Coxiella burnetii. *Infect Immun* 47:366–369.
  302. Akporiaye ET, Rowatt JD, Aragon AA, Baca OG. 1983. Lysosomal

- response of a murine macrophage-like cell line persistently infected with *Coxiella burnetii*. *Infect Immun* 40:1155–1162.
303. Roman MJ, Coriz PD, Baca OG. 1986. A proposed model to explain persistent infection of host cells with *Coxiella burnetii*. *J Gen Microbiol* 132:1415–1422.
  304. Buhles WC, Huxsoll DL, Ruch G, Kenyon RH, Elisberg BL. 1975. Evaluation of primary blood monocyte and bone marrow cell culture for the isolation of *Rickettsia rickettsii*. *Infect Immun* 12:1457–1463.
  305. Kelly PJ, Raoult D, Mason PR. 1991. Isolation of spotted fever group rickettsias from triturated ticks using a modification of the centrifugation-shell vial technique. *Trans R Soc Trop Med Hyg* 85:397–398. [http://dx.doi.org/10.1016/0035-9203\(91\)90303-G](http://dx.doi.org/10.1016/0035-9203(91)90303-G).
  306. Balraj P, Vestris G, Raoult D, Renesto P. 2009. Comparison of *Rickettsia conorii* growth within different cell lines by real-time quantitative PCR. *Clin Microbiol Infect* 15(Suppl 2):294–295. <http://dx.doi.org/10.1111/j.1469-0691.2008.02243.x>.
  307. Edouard S, Raoult D. 2013. Use of the plaque assay for testing the antibiotic susceptibility of intracellular bacteria. *Future Microbiol* 8:1301–1316. <http://dx.doi.org/10.2217/fmb.13.98>.
  308. McDade JE, Gerone PJ. 1970. Plaque assay for Q fever and scrub typhus rickettsiae. *Appl Microbiol* 19:963–965.
  309. Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, Roux V, Piette JC, Vandenesch F, Vital-Durand D, Marrie TJ. 2000. Cultivation of the bacillus of Whipple's disease. *N Engl J Med* 342:620–625. <http://dx.doi.org/10.1056/NEJM200003023420903>.
  310. Fenollar F, Birg ML, Gauduchon V, Raoult D. 2003. Culture of *Tropheryma whippelii* from human samples: a 3-year experience (1999 to 2002). *J Clin Microbiol* 41:3816–3822. <http://dx.doi.org/10.1128/JCM.41.8.3816-3822.2003>.
  311. Raoult D, La Scola B, Lecocq P, Lepidi H, Fournier PE. 2001. Culture and immunological detection of *Tropheryma whippelii* from the duodenum of a patient with Whipple disease. *JAMA* 285:1039–1043. <http://dx.doi.org/10.1001/jama.285.8.1039>.
  312. Raoult D, Fenollar F, Birg ML. 2006. Culture of *T. whippelii* from the stool of a patient with Whipple's disease. *N Engl J Med* 355:1503–1505. <http://dx.doi.org/10.1056/NEJMc061049>.
  313. Bentley SD, Maiwald M, Murphy LD, Pallen MJ, Yeats CA, Dover LG, Norbertczak HT, Besra GS, Quail MA, Harris DE, von Herbay A, Goble A, Rutter S, Squares R, Squares R, Barrell BG, Parkhill J, Relman DA. 2003. Sequencing and analysis of the genome of the Whipple's disease bacterium *Tropheryma whippelii*. *Lancet* 361:637–644. [http://dx.doi.org/10.1016/S0140-6736\(03\)12597-4](http://dx.doi.org/10.1016/S0140-6736(03)12597-4).
  314. Higo E, Capo C, Aurouze M, Tung CH, Gorvel JP, Raoult D, Mege JL. 2002. Survival of *Tropheryma whippelii*, the agent of Whipple's disease, requires phagosomal acidification. *Infect Immun* 70:1501–1506. <http://dx.doi.org/10.1128/IAI.70.3.1501-1506.2002>.
  315. Dawson JE, Candal FJ, George VG, Ades EW. 1993. Human endothelial cells as an alternative to DH82 cells for isolation of *Ehrlichia chaffeensis*, *E. canis*, and *Rickettsia rickettsii*. *Pathobiology* 61:293–296.
  316. Cheng C, Ganta RR. 2008. Laboratory maintenance of *Ehrlichia chaffeensis* and *Ehrlichia canis* and recovery of organisms for molecular biology and proteomics studies. *Curr Protoc Microbiol* Chapter 3:Unit 3A.1. <http://dx.doi.org/10.1002/9780471729259.mc03a01s9>.
  317. Brouqui P, Birg ML, Raoult D. 1994. Cytopathic effect, plaque formation, and lysis of *Ehrlichia chaffeensis* grown on continuous cell lines. *Infect Immun* 62:405–411.
  318. Chen SM, Popov VL, Feng HM, Wen J, Walker DH. 1995. Cultivation of *Ehrlichia chaffeensis* in mouse embryo, Vero, BGM, and L929 cells and study of *Ehrlichia*-induced cytopathic effect and plaque formation. *Infect Immun* 63:647–655.
  319. Heimer R, Tisdale D, Dawson JE. 1998. A single tissue culture system for the propagation of the agents of the human ehrlichioses. *Am J Trop Med Hyg* 58:812–815.
  320. Goodman JL, Nelson C, Vitale B, Madigan JE, Dumler JS, Kurtti TJ, Munderloh UG. 1996. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. *N Engl J Med* 334:209–215. <http://dx.doi.org/10.1056/NEJM199601253340401>.
  321. Carlyon JA. 2005. Laboratory maintenance of *Anaplasma phagocytophilum*. *Curr Protoc Microbiol* Chapter 3:Unit 3A.2. <http://dx.doi.org/10.1002/9780471729259.mc03a02s00>.
  322. Croy TR, Kuo CC, Wang SP. 1975. Comparative susceptibility of eleven mammalian cell lines to infection with trachoma organisms. *J Clin Microbiol* 1:434–439.
  323. Campbell LA, Kuo CC. 2009. Cultivation and laboratory maintenance of *Chlamydia pneumoniae*. *Curr Protoc Microbiol* Chapter 11:Unit 11B. <http://dx.doi.org/10.1002/9780471729259.mc11b01s12>.
  324. Scidmore MA. 2005. Cultivation and laboratory maintenance of *Chlamydia trachomatis*. *Curr Protoc Microbiol* Chapter 11:Unit 11A.1. <http://dx.doi.org/10.1002/9780471729259.mc11a01s00>.
  325. Ripa KT, Mardh PA. 1977. Cultivation of *Chlamydia trachomatis* in cycloheximide-treated McCoy cells. *J Clin Microbiol* 6:328–331.
  326. Cles LD, Stamm WE. 1990. Use of HL cells for improved isolation and passage of *Chlamydia pneumoniae*. *J Clin Microbiol* 28:938–940.
  327. Higgins JA, Radulovic S, Schriefer ME, Azad AF. 1996. *Rickettsia felis*: a new species of pathogenic *Rickettsia* isolated from cat fleas. *J Clin Microbiol* 34:671–674.
  328. Radulovic S, Higgins JA, Jaworski DC, Azad AF. 1995. In vitro and in vivo antibiotic susceptibilities of ELB rickettsiae. *Antimicrob Agents Chemother* 39:2564–2566. <http://dx.doi.org/10.1128/AAC.39.11.2564>.
  329. La Scola B, Meconi S, Fenollar F, Rolain JM, Roux V, Raoult D. 2002. Emended description of *Rickettsia felis* (Bouyer et al. 2001), a temperature-dependent cultured bacterium. *Int J Syst Evol Microbiol* 52:2035–2041. <http://dx.doi.org/10.1099/ijs.0.02070-0>.
  330. Saisongkroh W, El Karkoury K, Patrice JY, Bernard A, Rolain JM, Raoult D. 2012. Tryptose phosphate broth improves *Rickettsia felis* replication in mammalian cells. *FEMS Immunol Med Microbiol* 64:111–114. <http://dx.doi.org/10.1111/j.1574-695X.2011.00882.x>.
  331. Luce-Fedrow A, Macaluso KR, Richards AL. 2014. Growth of *Rickettsia felis* in *Drosophila melanogaster* S2 cells. *Vector Borne Zoonotic Dis* 14:101–110. <http://dx.doi.org/10.1089/vbz.2013.1370>.
  332. Mediannikov O, Sekeyova Z, Birg ML, Raoult D. 2010. A novel obligate intracellular gamma-proteobacterium associated with ixodid ticks, *Diplorickettsia massiliensis*, gen nov., sp. nov. *PLoS One* 5:e11478. <http://dx.doi.org/10.1371/journal.pone.0011478>.
  333. Birkbeck TH, Griffen AA, Reid HI, Laidler LA, Wadsworth S. 2004. Growth of *Piscirickettsia salmonis* to high titers in insect tissue culture cells. *Infect Immun* 72:3693–3694. <http://dx.doi.org/10.1128/IAI.72.6.3693-3694.2004>.
  334. Drancourt M, Jarlier V, Raoult D. 2002. The environmental pathogen *Mycobacterium ulcerans* grows in amphibian cells at low temperatures. *Appl Environ Microbiol* 68:6403–6404. <http://dx.doi.org/10.1128/AEM.68.12.6403-6404.2002>.
  335. Bell-Sakly L, Zwegarth E, Blouin EF, Gould EA, Jongejan F. 2007. Tick cell lines: tools for tick and tick-borne disease research. *Trends Parasitol* 23:450–457. <http://dx.doi.org/10.1016/j.pt.2007.07.009>.
  336. Herrin B, Mahapatra S, Blouin EF, Shaw EI. 2011. Growth of *Coxiella burnetii* in the *Ixodes scapularis*-derived IDE8 tick cell line. *Vector Borne Zoonotic Dis* 11:917–922. <http://dx.doi.org/10.1089/vbz.2010.0126>.
  337. Pornwiroon W, Pourciau SS, Foil LD, Macaluso KR. 2006. *Rickettsia felis* from cat fleas: isolation and culture in a tick-derived cell line. *Appl Environ Microbiol* 72:5589–5595. <http://dx.doi.org/10.1128/AEM.00532-06>.
  338. Sakamoto JM, Azad AF. 2007. Propagation of arthropod-borne *Rickettsia* spp. in two mosquito cell lines. *Appl Environ Microbiol* 73:6637–6643. <http://dx.doi.org/10.1128/AEM.00923-07>.
  339. Zhang X, Ren X, Norris DE, Rasgon JL. 2012. Distribution and infection frequency of '*Candidatus Rickettsia amblyommii*' in Maryland populations of the lone star tick (*Amblyomma americanum*) and culture in an *Anopheles gambiae* mosquito cell line. *Ticks Tick Borne Dis* 3:38–42. <http://dx.doi.org/10.1016/j.tbd.2011.09.010>.
  340. Sunyakumthorn P, Bourchookarn A, Pornwiroon W, David C, Barker SA, Macaluso KR. 2008. Characterization and growth of polymorphic *Rickettsia felis* in a tick cell line. *Appl Environ Microbiol* 74:3151–3158. <http://dx.doi.org/10.1128/AEM.00025-08>.
  341. Munderloh UG, Tate CM, Lynch MJ, Howerth EW, Kurtti TJ, Davidson WR. 2003. Isolation of an *Anaplasma* sp. organism from white-tailed deer by tick cell culture. *J Clin Microbiol* 41:4328–4335. <http://dx.doi.org/10.1128/JCM.41.9.4328-4335.2003>.
  342. Varela AS, Luttrell MP, Howerth EW, Moore VA, Davidson WR, Stallknecht DE, Little SE. 2004. First culture isolation of *Borrelia lonestari*, putative agent of southern tick-associated rash illness. *J Clin Microbiol* 42:1163–1169. <http://dx.doi.org/10.1128/JCM.42.3.1163-1169.2004>.
  343. Simser JA, Palmer AT, Fingerle V, Wilske B, Kurtti TJ, Munderloh UG. 2002. *Rickettsia monacensis* sp. nov., a spotted fever group *Rickettsia*, from ticks (*Ixodes ricinus*) collected in a European city park. *Appl*

- Environ Microbiol 68:4559–4566. <http://dx.doi.org/10.1128/AEM.68.9.4559-4566.2002>.
344. Cory J, Yunker CE. 1974. Rickettsial plaques in mosquito cell monolayers. *Acta Virol* 18:512–513.
345. Horta MC, Labruna MB, Durigon EL, Schumaker TT. 2006. Isolation of *Rickettsia felis* in the mosquito cell line C6/36. *Appl Environ Microbiol* 72:1705–1707. <http://dx.doi.org/10.1128/AEM.72.2.1705-1707.2006>.
346. O'Neill SL, Pettigrew MM, Sinkins SP, Braig HR, Andreadis TG, Tesh RB. 1997. In vitro cultivation of *Wolbachia pipiensis* in an *Aedes albopictus* cell line. *Insect Mol Biol* 6:33–39.
347. Voronin D, Tran-Van V, Potier P, Mavingui P. 2010. Transinfection and growth discrepancy of *Drosophila* *Wolbachia* strain wMel in cell lines of the mosquito *Aedes albopictus*. *J Appl Microbiol* 108:2133–2141. <http://dx.doi.org/10.1111/j.1365-2672.2009.04621.x>.
348. Rovey C, Renesto P, Crapoulet N, Matsumoto K, Parola P, Ogata H, Raoult D. 2005. Transcriptional response of *Rickettsia conorii* exposed to temperature variation and stress starvation. *Res Microbiol* 156:211–218. <http://dx.doi.org/10.1016/j.resmic.2004.09.002>.
349. Uchiyama T. 2005. Growth of typhus group and spotted fever group rickettsiae in insect cells. *Ann N Y Acad Sci* 1063:215–221. <http://dx.doi.org/10.1196/annals.1355.034>.
350. El-Etr SH, Yan L, Cirillo JD. 2001. Fish monocytes as a model for mycobacterial host-pathogen interactions. *Infect Immun* 69:7310–7317. <http://dx.doi.org/10.1128/IAI.69.12.7310-7317.2001>.
351. Fryer JL, Lannan CN, Giovannoni SJ, Wood ND. 1992. *Piscirickettsia salmonis* gen. nov., sp. nov., the causative agent of an epizootic disease in salmonid fishes. *Int J Syst Bacteriol* 42:120–126. <http://dx.doi.org/10.1099/00207713-42-1-120>.
352. Marrero M, Raoult D. 1989. Centrifugation-shell vial technique for rapid detection of Mediterranean spotted fever rickettsia in blood culture. *Am J Trop Med Hyg* 40:197–199.
353. Hudson JB, Misra V, Mosmann TR. 1976. Cytomegalovirus infectivity: analysis of the phenomenon of centrifugal enhancement of infectivity. *Virology* 72:235–243. [http://dx.doi.org/10.1016/0042-6822\(76\)90326-3](http://dx.doi.org/10.1016/0042-6822(76)90326-3).
354. Weiss E, Dressler HR. 1960. Centrifugation and Rickettsia and viruses onto cells and its effect on infection. *Proc Soc Exp Biol Med* 103:691–695.
355. Vestris G, Rolain JM, Fournier PE, Birg ML, Enea M, Patrice JY, Raoult D. 2003. Seven years' experience of isolation of *Rickettsia* spp. from clinical specimens using the shell vial cell culture assay. *Ann N Y Acad Sci* 990:371–374. <http://dx.doi.org/10.1111/j.1749-6632.2003.tb07394.x>.
356. Birg ML, La Scola B, Roux V, Brouqui P, Raoult D. 1999. Isolation of *Rickettsia prowazekii* from blood by shell vial cell culture. *J Clin Microbiol* 37:3722–3724.
357. Raoult D, Vestris G, Enea M. 1990. Isolation of 16 strains of *Coxiella burnetii* from patients by using a sensitive centrifugation cell culture system and establishment of the strains in HEL cells. *J Clin Microbiol* 28:2482–2484.
358. Maurin M, Raoult D. 2000. Isolation in endothelial cell cultures of *Chlamydia trachomatis* LGV (serovar L2) from a lymph node of a patient with suspected cat scratch disease. *J Clin Microbiol* 38:2062–2064.
359. Bernit E, Veit V, La Scola B, Tissot-Dupont H, Gachon J, Raoult D, Harle JR. 2003. *Bartonella quintana* and *Mycobacterium tuberculosis* coinfection in an HIV-infected patient with lymphadenitis. *J Infect* 46:244–246. <http://dx.doi.org/10.1053/jinf.2002.1040>.
360. Fournier PE, Bernabeu L, Schubert B, Mutillod M, Roux V, Raoult D. 1998. Isolation of *Francisella tularensis* by centrifugation of shell vial cell culture from an inoculation eschar. *J Clin Microbiol* 36:2782–2783.
361. Fournier PE, Drancourt M, Lepidi H, Gevaudan MJ, Raoult D. 2000. Isolation of mycobacteria from clinical samples using the centrifugation-shell vial technique. *Eur J Clin Microbiol Infect Dis* 19:69–70. <http://dx.doi.org/10.1007/s100960050015>.
362. La Scola B, Michel G, Raoult D. 1999. Isolation of *Legionella pneumophila* by centrifugation of shell vial cell cultures from multiple liver and lung abscesses. *J Clin Microbiol* 37:785–787.
363. Rovey C, Rolain JM, Raoult D, Brouqui P. 2003. Shell vial culture as a tool for isolation of *Brucella melitensis* in chronic hepatic abscess. *J Clin Microbiol* 41:4460–4461. <http://dx.doi.org/10.1128/JCM.41.9.4460-4461.2003>.
364. Loridant S, Jaffar-Bandjee MC, La Scola B. 2011. Shell vial cell culture as a tool for *Streptococcus moniliformis* “resuscitation.” *Am J Trop Med Hyg* 84:306–307. <http://dx.doi.org/10.4269/ajtmh.2011.10-0466>.
365. Raoult D, Torres H, Drancourt M. 1991. Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of *Coxiella burnetii*. *Antimicrob Agents Chemother* 35:2070–2077. <http://dx.doi.org/10.1128/AAC.35.10.2070>.
366. Torres H, Raoult D. 1993. In vitro activities of ceftriaxone and fusidic acid against 13 isolates of *Coxiella burnetii*, determined using the shell vial assay. *Antimicrob Agents Chemother* 37:491–494. <http://dx.doi.org/10.1128/AAC.37.3.491>.
367. Ogata H, Claverie JM. 2005. Metagrowth: a new resource for the building of metabolic hypotheses in microbiology. *Nucleic Acids Res* 33(Suppl 1):D321–D324. <http://dx.doi.org/10.1093/nar/gki042>.
368. Renesto P, Raoult D. 2003. Genome analysis as a new and powerful tool to design suitable culture media. Application to *Tropheryma whippelii*. *Discov Med* 3:32–33.
369. Omsland A. 2012. Axenic growth of *Coxiella burnetii*. *Adv Exp Med Biol* 984:215–229. [http://dx.doi.org/10.1007/978-94-007-4315-1\\_11](http://dx.doi.org/10.1007/978-94-007-4315-1_11).
370. Omsland A, Cockrell DC, Fischer ER, Heinzen RA. 2008. Sustained axenic metabolic activity by the obligate intracellular bacterium *Coxiella burnetii*. *J Bacteriol* 190:3203–3212. <http://dx.doi.org/10.1128/JB.01911-07>.
371. Kersh GJ, Oliver LD, Self JS, Fitzpatrick KA, Massung RF. 2011. Virulence of pathogenic *Coxiella burnetii* strains after growth in the absence of host cells. *Vector Borne Zoonotic Dis* 11:1433–1438. <http://dx.doi.org/10.1089/vbz.2011.0670>.
372. Omsland A, Beare PA, Hill J, Cockrell DC, Howe D, Hansen B, Samuel JE, Heinzen RA. 2011. Isolation from animal tissue and genetic transformation of *Coxiella burnetii* are facilitated by an improved axenic growth medium. *Appl Environ Microbiol* 77:3720–3725. <http://dx.doi.org/10.1128/AEM.02826-10>.
373. Rolain JM, Fenollar F, Raoult D. 2011. In vitro activity of pentamidine against *Tropheryma whippelii*. *Int J Antimicrob Agents* 38:545–547. <http://dx.doi.org/10.1016/j.ijantimicag.2011.07.015>.
374. Fenollar F, Ponge T, La Scola B, Lagier JC, Lefebvre M, Raoult D. 2012. First isolation of *Tropheryma whippelii* from bronchoalveolar fluid and clinical implications. *J Infect* 65:275–278. <http://dx.doi.org/10.1016/j.jinf.2011.11.026>.
375. La Scola B, Fenollar F, Perreal C, Raoult D. 2011. Epidemiologic implications of the first isolation and cultivation of *Tropheryma whippelii* from a saliva sample. *Ann Intern Med* 154:443–444. <http://dx.doi.org/10.7326/0003-4819-154-6-201103150-00018>.
376. Haider S, Wagner M, Schmid MC, Sixt BS, Christian JG, Hacker G, Pichler P, Mechtler K, Muller A, Baranyi C, Toenshoff ER, Montanaro J, Horn M. 2010. Raman microspectroscopy reveals long-term extracellular activity of *Chlamydiae*. *Mol Microbiol* 77:687–700. <http://dx.doi.org/10.1111/j.1365-2958.2010.07241.x>.
377. Stephens RS, Kalman S, Lammel C, Fan J, Marathe R, Aravind L, Mitchell W, Olinger L, Tatusov RL, Zhao Q, Koonin EV, Davis RW. 1998. Genome sequence of an obligate intracellular pathogen of humans: *Chlamydia trachomatis*. *Science* 282:754–759. <http://dx.doi.org/10.1126/science.282.5389.754>.
378. Kelly PJ, Beati L, Mason PR, Matthewman LA, Roux V, Raoult D. 1996. *Rickettsia africae* sp. nov., the etiological agent of African tick bite fever. *Int J Syst Bacteriol* 46:611–614. <http://dx.doi.org/10.1099/00207713-46-2-611>.
379. Fujita H, Fournier PE, Takada N, Saito T, Raoult D. 2006. *Rickettsia asiatica* sp. nov., isolated in Japan. *Int J Syst Evol Microbiol* 56:2365–2368. <http://dx.doi.org/10.1099/ijs.0.64177-0>.
380. Stenos J, Roux V, Walker D, Raoult D. 1998. *Rickettsia honei* sp. nov., the aetiological agent of Flinders Island spotted fever in Australia. *Int J Syst Bacteriol* 48(Part 4):1399–1404.
381. Beati L, Peter O, Burgdorfer W, Aeschlimann A, Raoult D. 1993. Confirmation that *Rickettsia helvetica* sp. nov. is a distinct species of the spotted fever group rickettsiae. *Int J Syst Bacteriol* 43:521–526. <http://dx.doi.org/10.1099/00207713-43-3-521>.
382. Fournier PE, Takada N, Fujita H, Raoult D. 2006. *Rickettsia tamurae* sp. nov., isolated from *Amblyomma testudinarium* ticks. *Int J Syst Evol Microbiol* 56:1673–1675. <http://dx.doi.org/10.1099/ijs.0.64134-0>.
383. Sekeyova Z, Roux V, Xu W, Rehacek J, Raoult D. 1998. *Rickettsia slovacica* sp. nov., a member of the spotted fever group rickettsiae. *Int J Syst Bacteriol* 48(Part 4):1455–1462.
384. Mediannikov O, Matsumoto K, Samoylenko I, Drancourt M, Roux V, Rydkina E, Davoust B, Tarasevich I, Brouqui P, Fournier PE. 2008. *Rickettsia raoultii* sp. nov., a spotted fever group rickettsia associated

- with Dermacentor ticks in Europe and Russia. *Int J Syst Evol Microbiol* 58:1635–1639. <http://dx.doi.org/10.1099/ijss.0.64952-0>.
385. Beati L, Meskini M, Thiers B, Raoult D. 1997. *Rickettsia aeschlimannii* sp. nov., a new spotted fever group rickettsia associated with *Hyalomma marginatum* ticks. *Int J Syst Bacteriol* 47:548–554. <http://dx.doi.org/10.1099/00207713-47-2-548>.
386. Beati L, Raoult D. 1993. *Rickettsia massiliae* sp. nov., a new spotted fever group Rickettsia. *Int J Syst Bacteriol* 43:839–840. <http://dx.doi.org/10.1099/00207713-43-4-839>.
387. Socolovschi C, Mediannikov O, Sokhna C, Tall A, Diatta G, Bassene H, Trape JF, Raoult D. 2010. *Rickettsia felis*-associated uneruptive fever, Senegal. *Emerg Infect Dis* 16:1140–1142. <http://dx.doi.org/10.3201/eid1607.100070>.
388. Richards AL, Jiang J, Omulo S, Dare R, Abdirahman K, Ali A, Sharif SK, Feikin DR, Breiman RF, Njenga MK. 2010. Human infection with *Rickettsia felis*, Kenya. *Emerg Infect Dis* 16:1081–1086. <http://dx.doi.org/10.3201/eid1607.091885>.
389. Mediannikov O, Fenollar F, Bassene H, Tall A, Sokhna C, Trape JF, Raoult D. 2013. Description of “yaaf”, the vesicular fever caused by acute *Rickettsia felis* infection in Senegal. *J Infect* 66:536–540. <http://dx.doi.org/10.1016/j.jinf.2012.10.005>.
390. Drancourt M, Raoult D, Lepidi H, Fenollar F, Birg ML, Bodaghi B, Hoang PL, Lelievre JD. 2003. Culture of *Tropheryma whippelii* from the vitreous fluid of a patient presenting with unilateral uveitis. *Ann Intern Med* 139:1046–1047. <http://dx.doi.org/10.7326/0003-4819-139-12-200312160-00025>.
391. Puechal X, Fenollar F, Raoult D. 2007. Cultivation of *Tropheryma whippelii* from the synovial fluid in Whipple’s arthritis. *Arthritis Rheum* 56:1713–1718. <http://dx.doi.org/10.1002/art.22596>.
392. La Scola B, Mallet MN, Grimont PA, Raoult D. 2002. Description of *Afipia birgiae* sp. nov. and *Afipia massiliensis* sp. nov. and recognition of *Afipia felis* genospecies A. *Int J Syst Evol Microbiol* 52:1773–1782. <http://dx.doi.org/10.1099/ijss.0.02149-0>.
393. Campocasso A, Boughalmi M, Fournous G, Raoult D, La Scola B. 2012. *Legionella tunisiensis* sp. nov. and *Legionella massiliensis* sp. nov., isolated from environmental water samples. *Int J Syst Evol Microbiol* 62:3003–3006. <http://dx.doi.org/10.1099/ijss.0.037853-0>.
394. Pagnier I, Raoult D, La Scola B. 2011. Isolation and characterization of *Reyranelia massiliensis* gen. nov., sp. nov. from freshwater samples by using an amoeba co-culture procedure. *Int J Syst Evol Microbiol* 61:2151–2154. <http://dx.doi.org/10.1099/ijss.0.025775-0>.
395. La Scola B, Barrassi L, Raoult D. 2004. A novel alpha-proteobacterium, *Nordella oligomobilis* gen. nov., sp. nov., isolated by using amoebal cocultures. *Res Microbiol* 155:47–51. <http://dx.doi.org/10.1016/j.resmic.2003.09.012>.
396. La Scola B, Mallet MN, Grimont PA, Raoult D. 1996. 2003. *Bosea eneeae* sp. nov., *Bosea massiliensis* sp. nov. and *Bosea vestrisii* sp. nov., isolated from hospital water supplies, and emendation of the genus *Bosea* (Das et al.). *Int J Syst Evol Microbiol* 53:15–20.
397. Adekambi T, Raoult D, Drancourt M. 2006. *Mycobacterium barrassiae* sp. nov., a *Mycobacterium moriokaense* group species associated with chronic pneumonia. *J Clin Microbiol* 44:3493–3498. <http://dx.doi.org/10.1128/JCM.00724-06>.
398. Ulger-Toprak N, Liu C, Summanen PH, Finegold SM. 2010. *Murdochella asaccharolytica* gen. nov., sp. nov., a Gram-stain-positive, anaerobic coccus isolated from human wound specimens. *Int J Syst Evol Microbiol* 60:1013–1016. <http://dx.doi.org/10.1099/ijss.0.015909-0>.
399. Wurdemann D, Tindall BJ, Pukall R, Lunsdorf H, Strompl C, Namuth T, Nahrstedt H, Wos-Oxley M, Ott S, Schreiber S, Timmis KN, Oxley AP. 2009. *Gordonibacter pamelaeeae* gen. nov., sp. nov., a new member of the Coriobacteriaceae isolated from a patient with Crohn’s disease, and reclassification of *Eggerthella hongkongensis* Lau et al. 2006 as *Paraeggerthella hongkongensis* gen. nov., comb. nov. *Int J Syst Evol Microbiol* 59:1405–1415. <http://dx.doi.org/10.1099/ijss.0.005900-0>.

**Jean-Christophe Lagier**, M.D., Ph.D., who specializes in infectious diseases, has been an associate professor at the Faculty of Medicine of Marseille, Aix Marseille University, since 2013. His clinical medical activity occurs at the University Hospital Institute Méditerranée Infection of Marseille. His research interests include *Tropheryma whippelii* infections and gut microbiota diversity, which he has specifically explored by culture on the team of D. Raoult since 2007. He coordinates with S. Khelaifa, the culturomics team directed by Prof. D. Raoult. By October 2014, Dr. Lagier had coauthored more than 85 publications in the international literature.



**Sophie Edouard**, Pharm.D., Ph.D., is a microbiologist specializing in diagnosing infectious diseases, specifically infections caused by intracellular bacteria, at Aix Marseille University, France. She obtained the title of doctor of pharmacy in 2011. Subsequently, she obtained her Ph.D. at the Faculty of Medicine of Marseille, Aix Marseille University, France, under the direction of Didier Raoult in 2013. She is now in charge of diagnosing and managing infection with fastidious bacteria at the infectious diseases department of the University Hospital of Marseille and in the French reference center for the diagnosis of rickettsioses, bartonellosis, and Q fever. She continues her research activity with the team of Didier Raoult. Her research interests focus on the diagnosis of and culture techniques for fastidious and vector-borne bacteria, including *C. burnetii*, *Bartonella* spp., *Rickettsia* spp., and *Anaplasma* spp.



**Isabelle Pagnier**, Pharm.D., Ph.D., is a French pharmacist and associate professor of microbiology at the Faculty of Pharmacy, and her research activity occurs at the Faculty of Medicine, Aix Marseille University. She completed her Ph.D. under the direction of Prof. Bernard La Scola. Her research interests focus on amoeba-associated microorganisms, primarily giant viruses such as *Mimiviridae* and marseilleviruses. Since 2013, she has been in charge of the scientific management of the electron microscopy platform of the URMITE laboratory, supervising structural and morphological studies of diverse bacteria, viruses, and microorganisms associated with protozoa. She has published more than 30 research articles regarding protozoan-associated microorganisms.



**Oleg Mediannikov**, M.D., Ph.D., graduated from the Medical University in Khabarovsk, Russia, in 1998 and specializes in infectious diseases. He obtained his Ph.D. in 2004, identifying the role of *Rickettsia*. He joined Didier Raoult’s team in France, focusing on vector-borne diseases, including anaplasmosis, spotted fevers, borreliosis, and their vectors. Since 2011, he has led a research group within the IRD component in Senegal, where he continues his studies of the origins of acute febrile diseases in Africa, particularly emerging vector-borne diseases (not only relapsing fever, spotted fevers, and bartonellosis but also filariosis and malaria). He is an expert on the isolation of fastidious bacteria, particularly intracellular ones.



*Continued next page*

**Michel Drancourt**, M.D., Ph.D., is a professor of medical microbiology at Aix Marseille University at Marseilles Medical School. He graduated in Marseille and visited the CDC in Atlanta, GA, as a postdoc. He developed expertise in paleomicrobiology and fastidious organisms, including mycobacteria, archaea, and planctomycetes.



**Didier Raoult**, M.D., Ph.D., who specializes in infectious diseases, is a professor of microbiology at the Faculty of Medicine of Marseille, Aix Marseille University. In 1984, he created *ex nihilo* his research laboratory, the Rickettsia Unit. This unit has now become the Research Unit in Infectious and Tropical Emergent Diseases (URMITE), collaborating with the CNRS (National Center for the Scientific Research), the IRD (Institute of Research for Development), and INSERM (National Institute of Health and Medical Research). In 2011, he became the director of the University Hospital Institute Méditerranée Infection, which is a 600-person medical institute focused on infectious diseases. This facility includes the largest diagnostic and research microbiology laboratory in France. As of 2014, Prof. Raoult has published more than 1,900 indexed publications. In the last 30 years, he has cultured approximately 16% of the bacteria isolated for the first time in humans, including *T. whipplei*, in his laboratory and developed a culturomics team in 2011.

